Lorenzo Livi, nato a Pistoia il 04/10/1972
Professore Ordinario dal 2012
Laureato in Medicina e chirurgia
Specializzato in Radioterapia presso l’Università degli Studi di Firenze.
Specializzato in Oncologia Medica presso L’Università Cattolica di Roma.
Direttore della SODc Radioterapia Oncologica Dell’AOU Careggi.
Direttore della Unit Radiobiology e CyberKnife presso IFCA (Istituto fiorentino di Cura ed Assistenza)
Membro della Commissione LEA presso in Ministero della Salute
LORENZO LIVI
Codice fiscale
LVILNZ72R04G713L
Nazionalità
Italiana
Data di nascita
04/10/1972
Esperienza lavorativa
Dal 02/11/2002 fino ad Aprile 2011 ha svolto attività assistenziale nella Unità Operativa Complessa di Radioterapia Oncologica quale responsabile della patologia mammaria, urologica e dei sarcomi delle parti molli. E’ vice responsabile della Struttura Ambulatoriale della UO Complessa di Radioterapia (oltre 15000 visite annue). Dal 18/04/2011 al 18/04/2013 è stato responsabile della Unità di Radioterapia presso l’Istituto Santa Chiara di Firenze.
Ricercatore del Dipartimento di Fisiopatologia Clinica sezione di Radioterapia (Settore Scientifico Disciplinare MED 36) dell’Università degli Studi di Firenze dal 01/11/2002. Ricercatore confermato dal 01/11/2005.
Professore Ordinario di I Fascia confermato in Radioterapia dal 28/12/2012 presso il Dipartimento di Scienze Biomediche, Sperimentali e Cliniche dell’Università degli Studi di Firenze.
Dal 08/11/2013 è Direttore della SOD Radioterapia Oncologica presso Azienda Ospedaliero Universitaria Careggi di Firenze. E’ autore di oltre 300 pubblicazioni su riviste scientifiche, oltre a figurare come autore o co-autore in numerosi capitoli riguardanti le più svariate tematiche d’interesse oncologico.
INCARICHI ACCADEMICI E ISCRIZIONE A SOCIETA’ SCIENTIFICHE:
Radioterapia Oncologica nel quadriennio 01/01/2004-31/12/2008.
INSEGNAMENTI (2014-2025):
Corso di laurea in
Infermieristica (abilitante alla professione sanitaria di Infermiere) (B162)
Insegnamento
B017162 - PROCESSI E PERCORSI DIAGNOSTICO-TERAPEUTICO-ASSISTENZIALI
Modulo
B017164 - DIAGNOSTICA PER IMMAGINI E RADIOPROTEZIONE
TECNICHE ORTOPEDICHE (ABILITANTE ALLA PROFESSIONE SANITARIA DI TECNICO ORTOPEDICO) (B177)
B019737 - RADIODIAGNOSTICA, RADIOTERAPIA, RADIOPROTEZIONE E INFORMATICA
B019739 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA
TECNICHE DI RADIOLOGIA MEDICA, PER IMMAGINI E RADIOTERAPIA (ABILITANTE ALLA PROFESSIONE SANITARIA DI TECNICO DI RADIOLOGIA MEDICA) (B176)
B019938 - RADIOBIOLOGIA E RADIOPROTEZIONE
B019939 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA
B019978 - TECNICHE DI DIAGNOSTICA PER IMMAGINI III (RADIOTERAPIA)
B019979 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA
MEDICINA E CHIRURGIA (B120)
B014289 - SPECIALITA' MEDICHE (C.I.)
B014294 - RADIOTERAPIA
B011649 - DIAGNOSTICA PER IMMAGINI (C.I.)
B011650 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIA
Istruzione e formazione
Diploma di maturità classica presso il Liceo Classico Niccolò Forteguerri di Pistoia nel 1991. Si è iscritto al CdL in Medicina e Chirurgia, presso l’Università degli Studi di Firenze, nel Ottobre del 1991 e si è laureato nella I sessione di laurea dell’anno 1997 (14/07/1997) con la votazione di 110/110, discutendo una tesi sperimentale dal titolo: “trattamento radioterapico radicale nel carcinoma prostatico”, relatore Prof G.P. Biti. Successivamente si è iscritto alla Scuola di Specializzazione in Radioterapia Oncologica presso l’Università degli Studi di Firenze nel Dicembre 1997 e si è specializzato con la votazione di 70 e lode su 70 in data 31/10/2001. Ha conseguito inoltre nell’ A.A. 2008-2009 la Specializzazione in Oncologia Medica presso l’Università Cattolica del Sacro Cuore A. Gemelli di Roma.
Capacità e competenze personali
Madrelingua
italiana
Altre lingua
inglese
eccellente
.
Capacità e competenze tecniche
Padronanza nell’uso di Windows, Microsoft Office (Word, PowerPoint, Excel, Access).
Progettazione e realizzazione di database in Excel e Access.
Gestione, organizzazione e partecipazione alle attività di gruppi di ricerca nazionali e internazionali
PRINCIPAL INVESTIGATOR :
1629 Late toxicities and long-term quality of life in survivors of head and neck cancer
ACP-HN Impact of acupuncture on acute dysphagia in patients undergoing radio-chemotherapy
for squamous cell carcinoma of the head and neck: a prospective randomized phase 2 study
ADAURA A multicenter, phase 3, randomized, double-blind, placebo-controlled
study of the efficacy and safety of AZD9291 versus
placebo in patients with stage IB-IIIA non-small cell lung cancer positive for epidermal growth factor receptor after complete tumor resection with or without adjuvant chemotherapy
AIR Study: AIOCC Italian Registry on Head and Neck Carcinoma
AMGEN 510 20190009: a phase III study comparing AMG 510 and DOCETAXEL in subjects with non-small cell lung cancer and p.G21C mutation of KRAS
Quantitative analysis of blood concentration of palbo/ribo by mass spectrometry
ARTO A phase II randomized trial of Ablative Radiation Therapy in patients with Oligometastatic castration resistant prostate cancer
ARV 7CIRCULATING MICRO-RNA (miRNA) AND AR-V7 MUTATIONAL STATUS IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC): PRIMERA+ STUDY (PROSTATE CANCER INNOVATING MARKERS OF EXPECTED RESPONSE TO AGONIST LHRH+ ANDROGEN RECEPTOR INHIBITION)
ATLAS A randomized, double-blind, placebo-controlled, Phase 3 study of JNJ-56021927 in subjects with high-risk, localized or locally advanced prostate cancer receiving primary radiotherapy
AV-951-20-304, TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor, PAREXEL Number 257305.
NeoCOAST 2) D9077C00001 A Phase II Open-label, Multicentre, Randomised Study of Neoadjuvant and Adjuvant Treatment in Patients with Resectable, Early-stage (II to IIIA) Non-small Cell Lung Cancer
BACH-NET Combination therapy with Bevacizumab, Atezolizumab and Chemotherapy inpatients with non-small cell lung cancer (NSCLC) with EGFR mutation, pretreated with EGFR tyrosine kinase inhibitors: anobservational study
BURAN STUDY: “Studio BURAN di Buparlisib (AN2025) in combinazione con Paclitaxel rispetto a Paclitaxel da solo, in pazienti affetti da carcinoma a cellule squamose, ricorrente o metastatico, del collo e della testa” - Protocollo AN2025H0301
CABACARE “CABAzitaxel with or without prednisone in patients with metastatic CAstration REsistant prostate cancer (mCRPC) progressed during or after a previous docetaxel-based chemotherapy:a multi-center, prospective, two-arm, open label, non inferiority phase II study
CARE STUDY TOLLERABILITA’ ED EFFICACIA DI CAPECITABINA COME TRATTAMENTO ADIUVANTE IN PAZIENTI AFFETTE DA CARCINOMA MAMMARIO TRIPLO NEGATIVO TRATTATE DOPO INCOMPLETA RISPOSTA PATOLOGICA A CHEMIOTERAPIA NEOADIUVANTE. STUDIO RETROSPETTIVO MULTICENTRICO DI REAL-WORLD
COSTAR LUNG 213410 A RANDOMIZED, OPEN LABEL PHASE 2/3 STUDY COMPARING COBOLIMAB + DOSTARLIMAB + DOCETAXEL TO DOSTARLIMAB + DOCETAXEL TO DOCETAXEL ALONE IN PARTICIPANTS WITH ADVANCED NON-SMALL CELL LUNG CANCER WHO HAVE PROGRESSED ON PRIOR ANTI PD (L)1 THERAPY AND CHEMOTHERAPY
D361DC00001 Capitello 292 "Capivasertib + fulvestrant + palbociclib in endocrine resistant HR+ BC
DERN IN EBV RELATED NASOPHARYNGEAL CARCINOMA (NPC) AS A MODEL FOR RANK-MEDIATED IMMUNOLOGIC MODULATION OF VIRUS-RELATED TUMOURS
DUART: Studio internazionale di fase II, in aperto, multicentrico su DURVALUMAB in seguito a radioterapia in pazienti con carcinoma polmonare non a piccole cellule allo stadio III non resecabile che non sono idonei alla chemioterapia
DUCRO-HN Anti PD-L1 Durvalumab (MEDI4736) associato a Cetuximab e radioterapia nel carcinoma squamocellulare del testa collo localmente avanzato: studio di fase I/II
E2 RADIATE 1811 (SPE15112) EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
EF-25 METIS Pivotal, open-label, randomized study of radiosurgery with or without Tumor Treating Fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC)
ELDERLY Il ruolo della valutazione geriatrica nella personalizzazione della scelta terapeutica dell’anziano: studio nei pazienti con carcinoma localmente avanzato del distretto testa-collo
EMBER-3 Eli Lilly J2J-OX-JZLC ELI LILLY A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator’s Choice of Endocrine Therapy, and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy
EMBER-4 Eli Lilly J2J-MC-JZLH: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
EORTC 1617 Follow-up in Early and Locally Advanced Breast Cancer Patients
EORTC 1721 Understanding the long-term implications of treatment of rare brain tumours on health-related quality of life: A European cross-sectional study’
EORTC Study 1976 - TOLERANCE: A 3 arm randomized study on healTh-related quality Of Life of EldeRly pAtients with advaNced soft tissue sarComa undergoing doxorubicin every three weeks or doxorubicin weekly or cyclophosphamide plus prednisolone treatment
EPIK-B2: A two part, Phase III, multicenter, randomized (1:1), double-blind, placebo-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with trastuzumab and pertuzumab as maintenance therapy in patients with HER2-positive advanced breast cancer with a PIK3CA mutation
EPIK-B5 CBYL719C2303 A Phase III, randomized, double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, who progressed on or after aromatase inhibitor and a CDK4/6 inhibitor.
EPROPA European Program for ROutine testing of Patients with Advanced lung cancer
EUROPA STUDIO DI FASE II-III RANDOMIZZATO, MULTICENTRICO, CON TERAPIA ENDOCRINA O IRRADIAZIONE PARZIALE DELLA MAMMELLA ESCLUSIVA IN DONNE DI ETÀ ≥70 ANNI CON TUMORI DELLA MAMMELLA LUMINALE-A IN STADIO INIZIALE
GIM 10 A phase III clinical study comparing concomitant versus sequential administration of chemotherapy and aromatase inhibitors as adjuvant treatment of postmenopausal patients with hormone-sensitive breast cancer.
GIM13 Studio Osservazionale Longitudinale di Coorte sulle scelte terapeutiche del carcinoma mammario metastatico HER2‐negativo nella pratica clinica Italiana
GSK 213824 PLATFORM - A Phase 2, Randomized, Open-label Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated Locally Advanced/Metastatic Programmed Death Ligand 1-Positive Non-Small-Cell-Lung-Cancer
HPV late elderly Pattern of practice in late elderly (>75 years) patients with HPV positive oropharyngeal cancer: a multicenter retrospective study
IGRT-IMRT Randomized Phase III Study of Chemoradiotherapy in Locally Advanced OropharyngealSquamous Cell Carcinoma: Moderately Hypofractionated IGRT-IMRT vs. Conventional Fractionated IMRT
IMPASSION 132 STUDIO DI FASE III, RANDOMIZZATO, MULTICENTRICO, IN DOPPIO CIECO E CONTROLLATO CON PLACEBO VOLTO A VALUTARE L'EFFICACIA E LA SICUREZZA DI ATEZOLIZUMAB + CHEMIOTERAPIA IN PAZIENTI AFFETTI DA CARCINOMA MAMMARIO TRIPLO NEGATIVO RICORRENTE CON RECIDIVA PRECOCE (INOPERABILE LOCALMENTE AVANZATO O METASTATICO)
IMREAL OSSERVAZIONALE “STUDIO NON INTERVENTISTICO, MULTICENTRICO E A COORTI MULTIPLE VOLTO A VALUTARE GLI OUTCOMES E LA SICUREZZA DI ATEZOLIZUMAB IN CONDIZIONI REALI IN PAZIENTI TRATTATI NELLA NORMALE PRATICA CLINICA”
IMVOKE STUDIO DI FASE III, MULTICENTRICO, RANDOMIZZATO, IN DOPPIO CIECO E CONTROLLATO CON PLACEBO VOLTO A VALUTARE ATEZOLIZUMAB (ANTICORPO ANTI−PD-L1) COME TERAPIA ADIUVANTE DOPO TRATTAMENTO LOCALE DEFINITIVO IN PAZIENTI AFFETTI DA CARCINOMA A CELLULE SQUAMOSE DELLA TESTA E DEL COLLO LOCALMENTE AVANZATO AD ALTO RISCHI
INTERLINK-1 (D7310C00001) "A Phase 3 Randomized, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Patients WithRecurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor"
INVIDI-a VACCINI “Indicazione al vaccino anti-influenzale durante immunoterapia oncologica”
ISES2 ANALISI PROSPETTICA MULTICENTRICA SUL RAPPORTO TRA STATUS SOCIODEMOGRAFICO, CARATTERISTICHE CLINICHE E BIOLOGICHE, ED OUTCOME CLINICO NEI PAZIENTI AFFETTI DA GLIOBLASTOMA DI NUOVA DIAGNOSI " (Rif CEAVC 20089 ).
ISG STS 1001 Localized high-risk soft tissue sarcomas of the extremities and trunk wall in adults: an integrating approach comprising standard vs histotype-tailored neoadjuvant chemotherapy
KEYNOTE 412 A Phase III Randomized, Double-Blind Study of Pembrolizumab/Placebo In Combination With Chemoradiotherapy and as Maintenance Therapy in Subjects With Locally Advanced HNSCC
KEYNOTE 867 A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Subjects With Unresectable Stage I or IIa Non-Small Cell Lung Cancer (NSCLC)
KEYNOTE 992 A Phase 3, Randomized, Double-blind, Placebo-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Chemoradiotherapy (CRT) versus CRT Alone in Participants with Muscle-invasive Bladder Cancer (MIBC)
LEAP-007 A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475)with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS)greater than or equal to 1%
Lid ERA: A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GDC‑9545 COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR−POSITIVE, HER2‑NEGATIVE EARLY BREAST CANCER
MK 3475 U01 Umbrella: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with either Pembrolizumab in Combination with Chemotherapy or with Pembrolizumab Alone in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
MK 7339 012 A Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib vs Concurrent Chemoradiation Therapy Followed by Durvalumab in Participants with Unresectable, Locally Advanced, Stage III Non-Small Cell Lung Cancer (NSCLC)
MK 7339-013 A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Pembrolizumab (MK-3475) in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab with or without Olaparib (MK-7339), Compared to Concurrent Chemoradiation Therapy Alone in Participants with Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC)
MO39874 ELISSAR A PHASE IIIB, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO EVALUATE THE SAFETY OF ATEZOLIZUMAB (TECENTRIQ) PLUS NAB-PACLITAXEL OR PACLITAXEL IN THE TREATMENT OF LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER
MP-LALC Mk-3475-422 - A randomized phase II study of Pembrolizumab (MK-3475) as maintainance therapy in patients with unresectable stage III non-small cell lung cancer treated with definitive chemo-radiotherapy (MP-LALC- Maintainance Pembrolizumab in Locally Advanced Lung Cancer).
NEMO Nintedanib come terapia di mantenimento del mesotelioma pleurico maligno studio di fase II randomizzato in doppio cieco
NEUTRALITY Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced inoperable stage III NSCLC treated with Durvalumab included in the Italian Expanded Access Program (EAP)
NEVER Studio multicentrico di Fase II Non Elective Vulnerable Elderly Radiotherapy
OVIDIO Observational Study of secOnd line Vargatef® and docetaxel In the aDvanced setting for non-small cell lung cancer in the era of Immuno-Oncology
PACIFIC R Primi dati del mondo reale sui pazienti affetti da NSCLC non resecabile allo stadio III, trattati con Durvalumab dopo Chemioterapia
PACIFIC-4/RTOG-3515 A Phase III, Randomized, Placebo-controlled, Double-blind, International Study of Durvalumab Following Stereotactic Body RadiationMulti-center,Therapy (SBRT) for the Treatment of Patients with unresected Stage I/II,lymph-node negative Non-small Cell Lung Cancer
PACIFIC-9 "A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy"
PALLAS: PALbociclib CoLlaborative Adjuvant Study:A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standardadjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor eceptor 2 (HER2)-negative early breast cancer
PEGASUS (EORTC1414) Sperimentazione randomizzata, di Fase IIIb che mette a confronto la radioterapia in aggiunta a deprivazione androgenica adiuvante a lungo termine con un antagonista del GNRH rispetto a un agonista del GNRH in aggiunta a protezione del flare in pazienti con carcinoma prostatico localizzato o localmente avanzato ad altissimo rischio
For the third study (BX43361) defined as Master Screening Protocol, which will be used to carry out the centralized evaluation of tumor biomarkers (via NGS) and define the eligibility of a patient in one of the studies active on the platform, a feasibility evaluation at center level is not foreseen, as no local procedures are foreseen (attached synopsis).
PICASO STUDY ECOG P S 2 NSCLC PATIENTS RECEIVING FIRST-LINE TREATMENT IN THE IMUNOTHERAPY ERA: AN OBSERVATIONAL, PROSPECTIVE STUDY ABOUT CLINICIANS’ A TTITUDES AND SURVIVAL OUTCOMES
POINT Pembrolizumab e Olaparib nel cancro nasofaringeo recidivante/metastatico, resistente al platino
PREFER 2: Prospective observational study on the treatment of breast cancer during pregnancy and on the follow-up of women who had a pregnancy after diagnosis and treatment of breast cancer
PREFER Prospective observational study on fertility preservation in young patients diagnosed with invasive breast cancer.
PROFILO TROMBOTICO Studio del profilo trombotico in pazienti con tumore solido
Progetto carcinoma mammario Observational study on HR+/HER2- Mestastatic Breast Cancer patients treated with Abemaciclib. Chart Review (
PSICHE “PSMA-guided approach in patients with biochemical recurrence after radical prostatectomy: a prospective observational study.”
RALPH Radiomics in Locally Advanced oroPharyngeal HPV negative tumors Radiomics in HPV-negative locally advanced oropharyngeal cancer: prediction of local control (LC) after radiochemotherapy (RT-CT) by analysis of radiomic features extracted from contrast-enhanced CT staging images
REACTION Phase II study of etoposide and cisplatin/carboplatin, in combination or not with pembrolizumab, in extensive and untreated small cell lung cancer
REALKEY Prospective cohort study in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with first-line systemic treatment
REGOMA GB-1-2020 RegomaOss Regorafenib in pazienti con Glioblastoma recidivato. Uno studio osservazionale, multicentrico e prospettico
ROCK Radioterapia preOperatoria con CyberKnife nel trattamento del tumore mammario in fase iniziale: studio esplorativo
SAFE Monitoring and pharmacological prevention of anthracycline-induced cardiotoxicity in association or not with trastuzumab in the treatment of non-metastatic breast cancer: effects of treatment with ACE inhibitors and beta blockers
SAFE-FORWARD Cardiological monitoring and safety of ultra-hypofractionated whole breast irradiation after breast-conserving surgery for patients affected by breast cancer: an observational prospective cohort study
SAMANTHA A European disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2 positive unresectable locally advanced or metastatic breast cancer
Sancuso Granisetron transdermal system (gtds) in preventing nausea and vomiting induced by cisplatin-based chemotherapy and concurrent radiotherapy for head and neck cancer
SAVANNAH A single-arm, phase II study to evaluate the efficacy of Osimertinib administered in combination with Savolitinib in EGFRm+ and MET+ patients with locally advanced or metastatic non-small cell lung cancer who have progressed following treatment with Osimertinib.
SILIBRAIN
Skeleton Frequenza di Skeletal-related Events in pazienti affetti da tumore polmonare non a piccole cellule con mutazioni di EGFR e metastasi ossee sottoposti a trattamento di prima linea con osimertinib: studio prospettico osservazionale multicentrico
SKYSCRAPER A PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF ATEZOLIZUMAB PLUS TIRAGOLUMAB AND ATEZOLIZUMAB PLUS PLACEBO AS FIRST-LINE TREATMENT IN PATIENTS WITH PD-L1 POSITIVE SQUAMOUS CELL CARCINOMARECURRENT/METASTATIC OF THE HEAD AND NECK
SPA Trial - Prostate Stereotactic body radiation therapy with or without androgen deprivation therapy, a phase III randomized controlled trial
SPRINT: Sarcoma Preoperative Radiation with simultaneous INTegrated boost
STARR STereotacticsAlvageRadiotherapy for macroscopic prostate bed Recurrence after prostatectomy-a Prospective observational study-
STRAIT-LUC trial: Stereotactic Radiotherapy (SRT) in combination with Immunotherapy for the treatment of brain metastases from non-small cell lung cancer (NSCLC): a prospective, observational multicenter study
Studio BO42777 "A PHASE I-III, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE THERAPIES IN COHORTS OF BIOMARKER-SELECTED PATIENTS WITH LOCALLY ADVANCED, UNRESECTABLE STAGE III NON SMALL CELL LUNG CANCER"
studio CHRIPTO Chemo-Radiotherapy followed by Immunotherapy in Patients with Locally Advanced Non-Small Cell Lung Cancer: A Multicenter Retrospective Real-Life Study and Evaluation of the Safety and Feasibility of the Combined Treatment
STUDIO LA-HN
TERZO STADIO Observational study of treatment strategies inclinical practice in patients withstage III NSCLC progressing on consolidation therapy with Durvalumab
Trylinx A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensitymodulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy
ULTIMATE ULtra-hypofractionated radioTherapy for hIgh risk and low burden MetAstaTic hormone sEnsitive prostate carcinoma, an observational trial-
UPSTREAM 1559 A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck
ZEAL - 213400: A Phase 3, Randomized, Double-Blind Placebo-Controlled, Multicenter Study Comparing Niraparib (PARP inhibitors) plus Pembrolizumab versus Placebo plus Pembrolizumab as Maintenance Therapy in Patients Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab For Stage IIIb or IV Non-Small Cell Lung Cancer
FLUXUS(Fiducial-guided Lung Ultracentral X-radiotherapy through endoscopic UltraSound) trialStudio osservazionale prospettico per la valutazione della sicurezza e dell’efficacia della Radioterapia stereotassica (SBRT) guidata da fiducials in pazienti affetti da lesioni toraciche maligne ultracentrali primitive e secondarie:
ADAURA 2 “An international, double-blind, randomized, placebo-controlled, phase III study evaluating the efficacy and safety of adjuvant osimertinib versus placebo in patients with EGFR mutation-positive stage IA2-IA3 non-small cell lung cancer following complete tumor resection."
ADT Study:Tolerability and efficacy of adjuvant T-DM1 in patients with HER2-positive breast cancer after incomplete pathological response to neoadjuvant chemotherapy including anti-HER2 agents. A multicenter, real-world, retrospective-prospective study
A multicenter retrospective study on the prognostic impact of pregnancy in women with history of BRCA mutated breast cancer
Studio BREAK Germline pathogenic variant of BRCA1/2 in unresectable hormone-positive (ER and/or PgR) HER2-negative metastatic or locally advanced breast cancer treated with cyclin-dependent kinase inhibitors CDK 4/6 in combination with hormone therapy ()
XRAY Vision (tbc) MS202359_0002 A randomized, double-blind, placebo-controlled, 2-arm Phase III study to assess efficacy and safety of xevinapant and radiotherapy compared to placebo and radiotherapy for demonstrating improvement of disease-free survival in participants with resected squamous cell carcinoma of the head and neck, who are at high risk for relapse and are ineligible for high-dose cisplati
CAMBRIA-2 A Phase III, open-label, randomized study to evaluate the efficacy and safety of camizestrant (AZD9833, a next-generation oral selective estrogen receptor degrader) versus standard endocrine therapy (aromatase inhibitor or tamoxifen) as an adjuvant treatment for patients with ER+/HER2- early breastcancer at intermediate-high or high risk of recurrence who have completed definitive locoregional treatment and have no evidence of recurrent disease.
CAMBriA-1 D8531C00002 A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
ROSE STUDY - Non-Interventional, multicenter, prospective, cohort study assessing the quality of life and hormonal levels in premenopausal patients with hormone receptor-positive and HER-2-negative Early Breast Cancer in Italy
EORTC-2013-BTG reatment and outcome of patients with primary brain tumours diagnosed according to cIMPACT-NOW recommendations and the 2021 WHO classification
SERENA-4: A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease, SERENA-4
OSCAR: Oligometastatic Sarcoma treated with Curative intent Ablative Radiotherapy: OSCAR
REAL6T - Retrospective, Noninterventional Study Assessing the Real-Life Use of The Long-Acting 6-Month Triptorelin Formulation as A Treatment for Different Stages of Prostate Cancer in Italy –
MacroGenics_CP-MGC018-03A Phase 2/3, Randomized, Open-label, Study of MGC018 Versus Androgen Receptor Axis-targeted Therapy (Abiraterone or Enzalutamide) in Participants with Metastatic Castration-resistant Prostate Cancer
TEP MEET CET Phase II single-arm study of TEPotinib combined with CETuximab in RM Acronym
Amgen 20190341 con Sotorasib VS Pembrolizumab dal titolo: A Phase 3, multicenter, randomized, open label Study Evaluating Efficacy of Sotorasib Platinum Doublet Combination versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Patients with Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers, Negative for PD-L1, and Positive for KRAS pG12C. (CodeBreak202)
PERSIAN. APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial –
SUNRISE Studio mUlticentrico osservazioNale prospettico sull’impiego di analogo LHRH in formulazIone semeStrale nei paziEnti affetti da neoplasia della prostata
(eVOLVE-HNSCC) A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
CO44657 PIONERA A PHASE III RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT, BOTH COMBINED WITH A CDK4/6 INHIBITOR, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY
GSK219885_HNSCC R/M 1L A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck
(FIERCE-HN) Phase 3 Study of Ficlatuzumab in Combination with Cetuximab inSubjects with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma
ASPIRE GDF-15 levels and clinical/biological correlates in head and neck cancer patients with mucositis: developing a risk model for cachexia
Camizestrant Ophtalmological Safety Study A Multicentre, Open-Label, Study to Assess Ophthalmic Safety of Camizestrant in ER+/HER2- Early Breast Cancer Patients Who Are Either Initiating Adjuvant Endocrine-Based Therapy (CAMBRIA-2) or Have Been Treated with Standard Adjuvant Endocrine-Based Therapy For At Least 2 Years (CAMBRIA-1)
MK2870-012 Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Triple Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery
DYNASTY BREAST-03 phase III clinical study in BNT323/DB-1303 (ADC, Antibody Drug Conjugate), for patients with HER2-positive, First-line Metastatic Breast Cancer
AVEC-119 A single-arm phase II study of cetuximab plus platinum and taxane-based chemotherapy followed by AVElumab and Cetuximab as first-line therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) patients with PD-L1 combined positive score (CPS)≥1≤19: the immunotherapy sequence reversal
EORTC 2011-ReCare A prospective observational cohort on high-dose re-irradiation
LILLY – Abemaciclib as Adjuvant Therapy in High-Risk Early Breast Cancer: An Italian Observational Study on treatment persistence and adherence (IT-PATH)
INDICATES study INDIvidualized loCAl Therapy for patients with Ewing Sarcoma
BRIGHT "Prospective single-center study of tattoo-less radiotherapy treatments in patients with
breast cancer (Breast Cancer Radiation Therapy Innovation through Surface Guidance for
High Precision Tattoo-less Treatment)"
“IlsottoscrittoLorenzoLivi,consapevolecheledichiarazionifalsecomportanol’applicazionedellesanzioni pebnaliprevistedall’art.76del D.P.R. 445/2000, dichiara che le informazioni riportate nel curriculum viatae corrispondono a verità.Autorizzo il trattamento dei miei dati personali ai sensi del Dec. Leg.
30/06/2003,n.196eart.13GDPR679/16”;
Publications
Domine M, Clingan P, Hochmair MJ, Powell SF, Cheng SY, Bischoff HG, Peled N,
Grossi F, Jennens RR, Reck M, Hui R, Garon EB, Boyer M, Rubio-Viqueira B,
Novello S, Kurata T, Gray JE, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza MC,
Garassino MC; KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in
Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018 May
31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16. PMID:
SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L,
Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS;
ADAURA Investigators. Osimertinib in Resected <i>EGFR</i>-Mutated Non-Small-Cell
Lung Cancer. N Engl J Med. 2020 Oct 29;383(18):1711-1723. doi:
S, Su WC, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D,
Poole L, Bolanos A, Rukazenkov Y, Wu YL; ADAURA Investigators. Overall Survival
with Osimertinib in Resected <i>EGFR</i>-Mutated NSCLC. N Engl J Med. 2023 Jul
13;389(2):137-147. doi: 10.1056/NEJMoa2304594. Epub 2023 Jun 4. PMID: 37272535.
CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Tarazi J, Sridharan S, Sugg
J, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Zohren F, Shore ND;
EMBARK Study. Improved Outcomes with Enzalutamide in Biochemically Recurrent
Prostate Cancer. N Engl J Med. 2023 Oct 19;389(16):1453-1465. doi:
Azambuja E, Isacke CM, Harbeck N, Kaidar-Person O, Marangoni E, Offersen BV,
Rugo HS, Salvestrini V, Visani L, Morandi A, Lambertini M, Poortmans P, Livi L;
Consensus Panellist Group. International multidisciplinary consensus on the
integration of radiotherapy with new systemic treatments for breast cancer:
European Society for Radiotherapy and Oncology (ESTRO)-endorsed recommendations.
Lancet Oncol. 2024 Feb;25(2):e73-e83. doi: 10.1016/S1470-2045(23)00534-X. PMID:
Bernstein Molho R, Hilbers F, Pogoda K, Carrasco E, Punie K, Bajpai J,
Ignatiadis M, Moore HCF, Phillips KA, Toss A, Rousset-Jablonski C, Peccatori FA,
Renaud T, Ferrari A, Paluch-Shimon S, Fruscio R, Cui W, Wong SM, Vernieri C,
Ruddy KJ, Dieci MV, Matikas A, Rozenblit M, Villarreal-Garza C, De Marchis L,
Del Mastro L, Puglisi F, Del Pilar Estevez-Diz M, Rodriguez-Wallberg KA,
Mrinakova B, Meister S, Livraghi L, Clatot F, Yerushalmi R, De Angelis C,
Sánchez-Bayona R, Meattini I, Cichowska-Cwalinska N, Berlière M, Salama M, De
Giorgi U, Sonnenblick A, Chiodi C, Lee YJ, Maria C, Azim HA Jr, Boni L,
Partridge AH; BRCA BCY Collaboration. Pregnancy After Breast Cancer in Young
BRCA Carriers: An International Hospital-Based Cohort Study. JAMA. 2024 Jan
2;331(1):49-59. doi: 10.1001/jama.2023.25463. PMID: 38059899; PMCID:
Morgan G, Salvestrini V, Coles CE, Cortes J, Curigliano G, de Azambuja E,
Harbeck N, Isacke CM, Kaidar-Person O, Marangoni E, Offersen B, Rugo HS, Morandi
A, Lambertini M, Poortmans P, Livi L, Meattini I. Safety profile of cyclin-
dependent kinase (CDK) 4/6 inhibitors with concurrent radiation therapy: A
systematic review and meta-analysis. Cancer Treat Rev. 2023 Sep;119:102586. doi:
Feb;31:295-302. doi: 10.1016/j.breast.2016.07.022. Epub 2016 Aug 10. PMID:
Wardley A, Kaen D, Andrade L, Semiglazov V, Reinisch M, Patel S, Patre M,
Morales L, Patel SL, Kaul M, Barata T, O'Shaughnessy J; IMpassion131
controlled, randomised phase III trial of first-line paclitaxel with or without
atezolizumab for unresectable locally advanced/metastatic triple-negative breast
Epub 2021 Jul 1. PMID: 34219000.
Bonomo P, Greto D, Mangoni M, Scoccianti S, Lucidi S, Paoletti L, Fambrini M,
Bernini M, Sanchez L, Orzalesi L, Nori J, Bianchi S, Pallotta S, Livi L.
Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation
for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-
IMRT-Florence Trial. J Clin Oncol. 2020 Dec 10;38(35):4175-4183. doi:
Lenihan DJ, Marrazzo L, Curigliano G, Livi L. Association of Breast Cancer
Irradiation With Cardiac Toxic Effects: A Narrative Review. JAMA Oncol. 2021 Jun
1;7(6):924-932. doi: 10.1001/jamaoncol.2020.7468. PMID: 33662107.
O'Shaughnessy J, Harbeck N, Carey LA, Curigliano G, Llombart-Cussac A, Lim E,
García Tinoco ML, Sohn J, Mattar A, Zhang Q, Huang CS, Hung CC, Martinez
Rodriguez JL, Ruíz Borrego M, Nakamura R, Pradhan KR, Cramer von Laue C, Barrett
E, Cao S, Wang XA, Smyth LM, Bidard FC; EMBER-3 Study Group. Imlunestrant with
or without Abemaciclib in Advanced Breast Cancer. N Engl J Med. 2025 Mar
27;392(12):1189-1202. doi: 10.1056/NEJMoa2410858. Epub 2024 Dec 11. PMID:
Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał
M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington
KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL; KEYNOTE-412 Investigators.
Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent
chemoradiotherapy in patients with locally advanced squamous cell carcinoma of
the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.
Lancet Oncol. 2024 May;25(5):572-587. doi: 10.1016/S1470-2045(24)00100-1. Epub
2024 Mar 29. PMID: 38561010.
F, Gandini S, Alongi F, Bossi A, Cornford P, De Bari B, Fonteyne V, Hoskin P,
Pieters BR, Tree AC, Arcangeli S, Fuller DB, Franzese C, Hannoun-Levi JM,
Janoray G, Kerkmeijer L, Kwok Y, Livi L, Loi M, Miralbell R, Pasquier D, Pinkawa
M, Scher N, Scorsetti M, Shelan M, Toledano A, van As N, Vavassori A, Zilli T,
Pepa M, Ost P; on the behalf of the European Society for Radiotherapy, Oncology
Advisory Committee on Radiation Oncology Practice (ESTRO ACROP). Salvage
stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate
cancer radiotherapy: An ESTRO ACROP Delphi consensus. Cancer Treat Rev. 2021
Jul;98:102206. doi: 10.1016/j.ctrv.2021.102206. Epub 2021 Apr 20. PMID:
A, Smaniotto D, Barbara R, Lozza L, Vidali C, Borghesi S, Palumbo I, Huscher A,
Perrucci E, Baldissera A, Tolento G, Rovea P, Franco P, De Santis MC, Grazia AD,
Marino L, Meduri B, Cucciarelli F, Aristei C, Bertoni F, Guenzi M, Leonardi MC,
Livi L, Nardone L, De Felice F, Rosetto ME, Mazzuoli L, Anselmo P, Arcidiacono
F, Barbarino R, Martinetti M, Pasinetti N, Desideri I, Marazzi F, Ivaldi G,
Bonzano E, Cavallari M, Cerreta V, Fusco V, Sarno L, Bonanni A, Mangiacotti MG,
Prisco A, Buonfrate G, Andrulli D, Fontana A, Bagnoli R, Marinelli L, Reverberi
C, Scalabrino G, Corazzi F, Doino D, Di Genesio-Pagliuca M, Lazzari M, Mascioni
F, Pace MP, Mazza M, Vitucci P, Spera A, Macchia G, Boccardi M, Evangelista G,
Sola B, La Porta MR, Fiorentino A, Levra NG, Ippolito E, Silipigni S, Osti MF,
Mignogna M, Alessandro M, Ursini LA, Nuzzo M, Meattini I, D'Ermo G. AIRO Breast
Cancer Group <i>Best Clinical Practice 2022 Update</i>. Tumori. 2022
Jul;108(2_suppl):1-144. doi: 10.1177/03008916221088885. Erratum in: Tumori. 2022
Sep 20:3008916221130201. doi: 10.1177/03008916221130201. Erratum in: Tumori.
2022 Oct 21:3008916221135922. doi: 10.1177/03008916221135922. PMID: 36112842.
Di Brina L, Bonomo P, Giacomelli I, Meattini I, Mangoni M, Cappelli S, Cassani
S, Talamonti C, Bordi L, Livi L. Organs at risk in the brain and their dose-
constraints in adults and in children: a radiation oncologist's guide for
delineation in everyday practice. Radiother Oncol. 2015 Feb;114(2):230-8. doi:
G, D'Angelillo RM, Alitto AR, Augugliaro M, Triggiani L, Parisi S, Facchini G,
Banini M, Simontacchi G, Desideri I, Meattini I, Valicenti RK, Livi L; ARTO
Working Group members. Stereotactic Body Radiation Therapy and Abiraterone
Acetate for Patients Affected by Oligometastatic Castrate-Resistant Prostate
Cancer: A Randomized Phase II Trial (ARTO). J Clin Oncol. 2023 Dec
20;41(36):5561-5568. doi: 10.1200/JCO.23.00985. Epub 2023 Sep 21. PMID:
APBI-IMRT-Florence Trial (NCT02104895) Technique: From the Intensity Modulated
Radiation Therapy Trial to the Volumetric Modulated Arc Therapy Clinical
F, Scotti V, De Luca Cardillo C, Bastiani P, Orzalesi L, Casella D, Sanchez L,
Nori J, Fambrini M, Bianchi S. Accelerated partial breast irradiation using
intensity-modulated radiotherapy versus whole breast irradiation: 5-year
survival analysis of a phase 3 randomised controlled trial. Eur J Cancer. 2015
Mar;51(4):451-463. doi: 10.1016/j.ejca.2014.12.013. Epub 2015 Jan 17. PMID:
Sugawara S, Livi L, Basappa NS, Quantin X, Dudnik J, Ortiz DM, Mekhail T, Okpara
CE, Dutcus C, Zimmer Z, Samkari A, Bhagwati N, Csőszi T. Pembrolizumab With or
Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-
Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-
Blind, Phase 3 Trial. J Thorac Oncol. 2024 Jun;19(6):941-953. doi:
21: Christ SM, Alongi F, Ricardi U, Scorsetti M, Livi L, Balermpas P, Lievens Y,
Braam P, Jereczek-Fossa BA, Stellamans K, Ratosa I, Widder J, Peulen H, Dirix P,
Bral S, Ramella S, Hemmatazad H, Khanfir K, Geets X, Jeene P, Zilli T, Fournier
B, Ivaldi GB, Clementel E, Fortpied C, Oppong FB, Ost P, Guckenberger M. Cancer-
specific dose and fractionation schedules in stereotactic body radiotherapy for
oligometastatic disease: An interim analysis of the EORTC-ESTRO
E<sup>2</sup>-RADIatE OligoCare study. Radiother Oncol. 2024 Jun;195:110235.
doi: 10.1016/j.radonc.2024.110235. Epub 2024 Mar 19. PMID: 38508239.
Jul;51(11):1478-9. doi: 10.1016/j.ejca.2015.04.019. Epub 2015 May 18. PMID:
Osti MF, Fornarini G, Sisani M, Di Cataldo V, Detti B, Garlatti P, Bertini N,
Serni S, Minervini A, Livi L. PERSIAN trial (NCT05717660): an ongoing randomized
trial testing androgen deprivation therapy, apalutamide and stereotactic body
prostate cancer patients. Med Oncol. 2023 Dec 29;41(1):39. doi:
Curigliano G, Del Mastro L, De Placido S, Fabi A, Fortunato L, Generali D,
Gennari A, Gori S, Grandi G, Guarneri V, Klinger M, Livi L, Marchiò C, Palumbo
I, Panizza P, Pravettoni G, Pruneri G, Puglisi F, Sapino A, Tinterri C,
Turchetti D, De Laurentiis M. Parp-inhibitors in the therapeutic landscape of
breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An
Italian consensus paper and critical review. Cancer Treat Rev. 2024
Nov;130:102815. doi: 10.1016/j.ctrv.2024.102815. Epub 2024 Aug 21. PMID:
research and treatment. Biomed Res Int. 2014;2014:708383. doi:
26: Iorio GC, Denaro N, Livi L, Desideri I, Nardone V, Ricardi U. Editorial:
Advances in radiotherapy for head and neck cancer. Front Oncol. 2024 Jun
7;14:1437237. doi: 10.3389/fonc.2024.1437237. PMID: 38912069; PMCID:
Della Puppa A, Livi L, Perini Z, Zivelonghi E, Bulgarelli G, Pinzi V, Navarria
P, Clerici E, Scorsetti M, Ascolese AM, Osti MF, Anselmo P, Amelio D, Minniti G,
Scartoni D. Re-irradiation for recurrent intracranial meningiomas: Analysis of
clinical outcomes and prognostic factors. Radiother Oncol. 2024 Jun;195:110271.
doi: 10.1016/j.radonc.2024.110271. Epub 2024 Apr 7. PMID: 38588920.
Scartoni D. Response to Tugcu et al. Radiother Oncol. 2024 Aug;197:110378. doi:
Coles CE, Kaidar-Person O, Offersen B, de Azambuja E, Visani L, Cortes J,
Harbeck N, Rugo HS, Isacke CM, Marangoni E, Morandi A, Lambertini M, Poortmans
P, Livi L, Meattini I. Safety profile of trastuzumab-emtansine (T-DM1) with
concurrent radiation therapy: A systematic review and meta-analysis. Radiother
PMID: 37437610.
OD, Del Mastro L, Livi L, Castellano I, Bernardi D, Minelli M, Fortunato L;
ANISC Collaborative Group. Third national surgical consensus conference of the
Italian Association of Breast Surgeons (ANISC) on management after neoadjuvant
chemotherapy: The difficulty in reaching a consensus. Eur J Surg Oncol. 2024
Jul;50(7):108351. doi: 10.1016/j.ejso.2024.108351. Epub 2024 Apr 24. PMID:
Cataldo V, Valzano M, Visani L, Salvestrini V, Olmetto E, Desideri I, Meattini
I, Livi L. Quality of life after definitive treatment for bladder cancer: A
systematic review and meta-analysis. Radiother Oncol. 2024 Jan;190:110038. doi:
Roghi M, di Cataldo V, Fondelli S, Ingrosso G, Francolini G, Scartoni D, Sardaro
A, Pisani A, Scoccianti S, Aristei C, Livi L. Choline PET/CT in recurrent
prostate cancer. Front Oncol. 2023 Mar 21;13:1079808. doi:
Blasi L, Bria E, Cognetti F, Crinò L, De Laurentiis M, Del Mastro L, De Placido
S, Beano A, Ferraù F, Foladore S, Forcignanò R, Gamucci T, Garrone O, Gennari A,
Giordano M, Giotta F, Giovanardi F, Latini L, Livi L, Marchetti P, Mattioli R,
Michelotti A, Montemurro F, Putzu C, Riccardi F, Ricciardi G, Romagnoli E,
Sarobba G, Spazzapan S, Tagliaferri P, Tinari N, Tonini G, Turletti A, Verusio
C, Zambelli A, Mustacchi G. Clinical Outcomes of HER2-Negative Metastatic Breast
Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study.
Cancers (Basel). 2023 Dec 25;16(1):117. doi: 10.3390/cancers16010117. PMID:
38201545; PMCID: PMC10777910.
M, Rago L, Duroni G, Bruni A, Augurio A, Tramacere F, Trippa F, Russo D, Bottero
M, Tamburo M, Parisi S, Borghesi S, Lancia A, Gomellini S, Scoccianti S,
Stefanacci M, Vullo G, Statuto T, Miranda G, Santo B, Di Marzo A, Bellavita R,
Vinciguerra A, Livi L, Aristei C, Bertini N, Orsatti C, Detti B. Image-guided
moderately hypofractionated radiotherapy for localized prostate cancer: a
multicentric retrospective study (IPOPROMISE). Radiol Med. 2024
Apr;129(4):643-652. doi: 10.1007/s11547-024-01782-2. Epub 2024 Feb 19. PMID:
38369638; PMCID: PMC11021246.
Convolutional ARMA Filters. IEEE Trans Pattern Anal Mach Intell. 2022
Jul;44(7):3496-3507. doi: 10.1109/TPAMI.2021.3054830. Epub 2022 Jun 3. PMID:
radiation therapy after primary systemic therapy in cT1-2N1 breast cancer:
lesson from the RAPCHEM/BOOG 2010-03 trial. Ann Transl Med. 2023 Aug
30;11(10):366. doi: 10.21037/atm-23-1051. Epub 2023 Apr 11. PMID: 37675297;
PMCID: PMC10477657.
Lambertini M, Livi L, Kaidar-Person O, Poortmans P. Omission of radiation
therapy after breast-conserving surgery for biologically favourable tumours in
younger patients: The wrong answer to the right question. Radiother Oncol. 2024
Jan;190:110045. doi: 10.1016/j.radonc.2023.110045. Epub 2023 Dec 6. PMID:
Zamagni C, Zambelli A, Puglisi F. Risk-Based Therapeutic Strategies for
HER2-Positive Early Breast Cancer: A Consensus Paper. Clin Breast Cancer. 2023
Oct;23(7):e458-e469. doi: 10.1016/j.clbc.2023.07.006. Epub 2023 Jul 26. PMID:
Livi L, Santoni R. Current therapeutic options in metastatic castration-
resistant prostate cancer. Semin Oncol. 2018 Oct;45(5-6):303-315. doi:
Bertini N, La Mattina S, Orsatti C, Francolini G, Abenavoli EM, Livi L, Aristei
C, de Jong D, Al Feghali KA, Siva S, Becherini C. Biology-guided radiotherapy in
metastatic prostate cancer: time to push the envelope? Front Oncol. 2024 Sep
9;14:1455428. doi: 10.3389/fonc.2024.1455428. PMID: 39314633; PMCID:
Radiotherapy (SFRT) For Bone Metastases: Patient Selection And Perspectives.
Cancer Manag Res. 2019 Nov 5;11:9397-9408. doi: 10.2147/CMAR.S186630. PMID:
31807069; PMCID: PMC6842277.
Crucitta S, Iannopollo M, Mazzoni F, Ruglioni M, Tibaldi C, Olmetto E, Stasi I,
Baldini E, Allegrini G, Antonuzzo L, Morelli F, Pierini A, Panzeri N, Fogli S,
Chella A, Rolfo C, Danesi R. Clinical utility of Next Generation Sequencing of
plasma cell-free DNA for the molecular profiling of patients with NSCLC at
diagnosis and disease progression. Transl Oncol. 2024 Mar;41:101869. doi:
Recurrence quantification analysis of dynamic brain networks. Eur J Neurosci.
2021 Feb;53(4):1040-1059. doi: 10.1111/ejn.14960. Epub 2020 Sep 13. PMID:
Marvaso G, Montesi G, Parisi S, Triggiani L, Lambertini M, Livi L. Radiation
therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view
of the nation's young oncologists. ESMO Open. 2020 Apr;5(2):e000779. doi:
G, Salvestrini V, Meattini I, Livi L. Thermal Ablation versus SBRT in liver
tumours: pros and cons. Med Oncol. 2020 Apr 29;37(6):52. doi:
L, Jagsi R, Coles CE, Poortmans P, Meattini I. Equity, Diversity, and Inclusion
in Radiation Oncology: A Bibliometric Analysis and Critical Review. Int J Radiat
Oncol Biol Phys. 2023 Jun 1;116(2):232-245. doi: 10.1016/j.ijrobp.2023.02.026.
Epub 2023 Feb 23. PMID: 36841344.
G, de Azambuja E, Harbeck N, Rugo HS, Del Mastro L, Gennari A, Isacke CM, Vestmø
Maraldo M, Marangoni E, Nader Marta G, Mjaaland I, Salvestrini V, Spanic T,
Visani L, Morandi A, Lambertini M, Livi L, Coles CE, Poortmans P, Offersen BV.
Essential requirements for reporting radiation therapy in breast cancer clinical
trials: An international multi-disciplinary consensus endorsed by the European
Society for Radiotherapy and Oncology (ESTRO). Radiother Oncol. 2024
Jun;195:110060. doi: 10.1016/j.radonc.2023.110060. Epub 2023 Dec 19. PMID:
Salvestrini V, Meattini I, Livi L, Shin KH. Risk of radionecrosis in
HER2-positive breast cancer with brain metastasis receiving trastuzumab
emtansine (T-DM1) and brain stereotactic radiosurgery. Radiother Oncol. 2024
Oct;199:110461. doi: 10.1016/j.radonc.2024.110461. Epub 2024 Jul 25. PMID:
MG, Roghi M, Bertini N, Orsatti C, Mangoni M, Francolini G, Marani S, Giacomelli
I, Loi M, Pergolizzi S, Bonzano E, Aristei C, Livi L. Modulation of tumor-
associated macrophage activity with radiation therapy: a systematic review.
Strahlenther Onkol. 2023 Dec;199(12):1173-1190. doi: 10.1007/s00066-023-02097-3.
Epub 2023 Jun 22. PMID: 37347290; PMCID: PMC10673745.
Belgioia L, Loi M, Mangoni M, Lambertini M, Morandi A. Integrating radiation
therapy with targeted treatments for breast cancer: From bench to bedside.
Cancer Treat Rev. 2022 Jul;108:102417. doi: 10.1016/j.ctrv.2022.102417. Epub
2022 May 21. PMID: 35623219.
Meattini I, Scoccianti S, Masoni T, Ciabatti C, Turkaj A, Serni S, Minervini A,
Gacci M, Carini M, Livi L. Hypofractionation in prostate cancer: radiobiological
basis and clinical appliance. Biomed Res Int. 2014;2014:781340. doi:
Deprivation Therapy in Intermediate Prostate Cancer Treated With Radiation
Therapy: The Wide Heterogeneity and Complexity of an Apparently Simple
Loi M, Livi L. Artificial Intelligence in radiotherapy: state of the art and
future directions. Med Oncol. 2020 Apr 22;37(6):50. doi:
Scotti V. A narrative review of postoperative adjuvant radiotherapy for non-
small cell lung cancer. Mediastinum. 2022 Mar 25;6:4. doi: 10.21037/med-21-31.
PMID: 35340837; PMCID: PMC8841548.
Morelli I, Bertini N, Orzalesi L, Bernini M, Bianchi S, Simontacchi G, Livi L,
Desideri I. Anatomical assessment of local recurrence site in breast cancer
patients after breast reconstruction and post-mastectomy radiotherapy:
implications for radiation volumes and techniques. Radiol Med. 2024
Jun;129(6):845-854. doi: 10.1007/s11547-024-01812-z. Epub 2024 Apr 11. PMID:
38602657; PMCID: PMC11168998.
radiotherapy in elderly cancer patients. F1000Res. 2020 May 27;9:F1000 Faculty
Rev-447. doi: 10.12688/f1000research.21151.1. PMID: 32518630; PMCID: PMC7255897.
Delli Paoli C, Dominici L, Maragna V, Olmetto E, Meattini I, Desideri I, Bonomo
P, Greto D, Livi L. Soft tissue sarcomas: new opportunity of treatment with PARP
inhibitors? Radiol Med. 2019 Apr;124(4):282-289. doi: 10.1007/s11547-018-0877-4.
Epub 2018 Mar 26. PMID: 29582320.
S, Castellan L, Arpino G, Conte P, Di Meco F, Gennari A, Guarneri V, Visani L,
Livi L, Marchetti P, Puglisi F, Viale G, Del Mastro L, De Placido S, Curigliano
horizons for HER2-positive metastatic disease and promising prospects for brain
metastatic spread. Cancer Treat Rev. 2023 Nov;120:102618. doi:
G, Carini M, Serni S, Gacci M. Prognosis of men with penile metastasis and
malignant priapism: a systematic review. Oncotarget. 2017 Dec 18;9(2):2923-2930.
doi: 10.18632/oncotarget.23366. PMID: 29416825; PMCID: PMC5788693.
61: Meattini I, Desideri I, Francolini G, Vannini A, Perna M, Garlatti P, Grassi
R, Livi L. Systemic therapies and cognitive impairment for breast cancer: an
overview of the current literature. Med Oncol. 2017 May;34(5):74. doi:
S, Desideri I, Agresti B, Greto D, Buccoliero AM, Puppa AD, Sardi I, Livi L.
Pleomorphic Xanthoastrocytoma: a single institution retrospective analysis and a
review of the literature. Radiol Med. 2022 Oct;127(10):1134-1141. doi:
Marchionni A, Filippi AR, Livi L, Sanguineti G, Aristei C, Detti B. Stereotactic
body radiotherapy (SBRT) in combination with drugs in metastatic kidney cancer:
A systematic review. Crit Rev Oncol Hematol. 2021 Mar;159:103242. doi:
and yet it moves!: 2019 in review. Clin Transl Radiat Oncol. 2020 Mar
7;22:40-43. doi: 10.1016/j.ctro.2020.03.004. PMID: 32195379; PMCID: PMC7078121.
From twilight to starlight? Debating the role of chemoradiotherapy in gastric
cancer in the D2 dissection era. Radiol Med. 2024 Nov;129(11):1710-1719. doi:
Scoccianti S, Sun R, Livi L, Ingrosso G. Radiotherapy for papillary tumor of the
pineal region: A systematic review of the literature. Clin Neurol Neurosurg.
2020 Mar;190:105646. doi: 10.1016/j.clineuro.2019.105646. Epub 2019 Dec 21.
PMID: 31896492.
F, Bonzano E, Prisco A, Masiello V, La Rocca E, Spoto R, Becherini C, Blandino
G, Moscetti L, Colciago RR, Audisio RA, Brain E, Caini S, Hamaker M, Kaidar-
Person O, Lambertini M, Marrazzo L, Saieva C, Spanic T, Strnad V, Wheelwright S,
Poortmans PMP, Livi L; EUROPA Trial Investigators. Single-modality endocrine
therapy versus radiotherapy after breast-conserving surgery in women aged 70
years and older with luminal A-like early breast cancer (EUROPA): a preplanned
interim analysis of a phase 3, non-inferiority, randomised trial. Lancet Oncol.
2025 Jan;26(1):37-50. doi: 10.1016/S1470-2045(24)00661-2. Epub 2024 Dec 12.
PMID: 39675376.
of Radiomics for the Prediction of Radiation-Induced Toxicity in the IMRT Era:
Current State-of-the-Art. Front Oncol. 2020 Oct 6;10:1708. doi:
Detti B, Greto D, Simontacchi G, Grassi R, Scoccimarro E, Bonomo P, Mangoni M,
Desideri I, Di Cataldo V, Vernaleone M, Casati M, Pallotta S, Livi L. Local
treatment for relapsing glioblastoma: A decision-making tree for choosing
between reirradiation and second surgery. Crit Rev Oncol Hematol. 2021
Jan;157:103184. doi: 10.1016/j.critrevonc.2020.103184. Epub 2020 Nov 28. PMID:
Teriaca MA, Francolini G, Sardaro A, Aristei C, Filippi AR, Sanguineti G, Livi
necessary paradigm change. Cancer Treat Res Commun. 2021;27:100331. doi:
M, Salvestrini V, Livi L, Desideri I. Integration between Novel Imaging
Technologies and Modern Radiotherapy Techniques: How the Eye Drove the Chisel.
Cancers (Basel). 2022 Oct 27;14(21):5277. doi: 10.3390/cancers14215277. PMID:
36358695; PMCID: PMC9656145.
Sanguineti G, Siva S, Zilli T, Francolini G, Bellavita R, Aristei C, Livi L,
Detti B. A systematic review and meta-analysis on non-metastatic castration
resistant prostate cancer: The radiation oncologist's perspective. Semin Oncol.
2022 Oct;49(5):409-418. doi: 10.1053/j.seminoncol.2022.09.005. Epub 2022 Sep 24.
PMID: 36192243.
Franzese C, Greto D, Livi L, Bonomo P, Biti G. Management of inflammatory breast
cancer: focus on radiotherapy with an evidence-based approach. Cancer Treat Rev.
2013 Apr;39(2):119-24. doi: 10.1016/j.ctrv.2012.04.001. Epub 2012 May 6. PMID:
Pallotta S, Ricci R, Livi L. Advancing patient setup: A comprehensive scoping
review of tattoo-less techniques in radiation therapy. Crit Rev Oncol Hematol.
2024 Dec;204:104518. doi: 10.1016/j.critrevonc.2024.104518. Epub 2024 Sep 20.
PMID: 39299409.
Bottero M, Bossi A, Zilli T, Scartoni D, Livi L, Santoni R, Giacomelli I, Detti
Systematic Review and Meta-analysis. Eur Urol Oncol. 2020 Apr;3(2):183-197. doi:
Simontacchi G, Greto D, Desideri I, Meattini I, Nuyttens J, Livi L. Stereotactic
reirradiation for local failure of brain metastases following previous
radiosurgery: Systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020
Sep;153:103043. doi: 10.1016/j.critrevonc.2020.103043. Epub 2020 Jul 2. PMID:
Santis MC, Fontana A, Franco P, Gentilini OD, Livi L, Meduri B, Parisi S,
Pasinetti N, Prisco A, Rocco N. Breast reconstruction and radiation therapy: An
Italian expert Delphi consensus statements and critical review. Cancer Treat
PMID: 34126314.
Gravas S, Carini M, Serni S. Quality of Life and Sexual Health in the Aging of
PCa Survivors. Int J Endocrinol. 2014;2014:470592. doi: 10.1155/2014/470592.
Epub 2014 Mar 17. Erratum in: Int J Endocrinol. 2015;2015:675101. doi:
Lorenzetti V, Colombo F, Morelli V, Ganovelli M, Caprara L, Orsatti C, Burchini
L, Frosini G, Bertini N, Loi M, Simontacchi G, Greto D, Desideri I, Meattini I,
Livi L. Pattern of recurrence after stereotactic body radiotherapy for para-
aortic oligo-recurrent prostate cancer, a multicentric analysis. Radiol Med.
2023 Nov;128(11):1423-1428. doi: 10.1007/s11547-023-01701-x. Epub 2023 Aug 19.
PMID: 37597125.
Casà C, Pieters BR, Russi E, Livi L, Corvò R, Giovagnoni A, Ricardi U, Valentini
V, Magrini SM; Directors of the Italian Radiation Oncology Schools. Current
state of interventional radiotherapy (brachytherapy) education in Italy: results
of the INTERACTS survey. J Contemp Brachytherapy. 2019 Feb;11(1):48-53. doi:
Radiation therapy for young women with early breast cancer: Current state of the
Desideri I, Lorenzetti V, Scoccimarro E, Greto D, Livi L. Regorafenib in
glioblastoma recurrence: A case report. Cancer Treat Res Commun. 2021;26:100263.
doi: 10.1016/j.ctarc.2020.100263. Epub 2020 Dec 10. PMID: 33338858.
M, De Felice F, Mazzola R, Caini S, Livi L, Bonomo P. Palliative radiotherapy in
older adults with head and neck squamous cell carcinoma: A systematic review.
Oral Oncol. 2021 Aug;119:105355. doi: 10.1016/j.oraloncology.2021.105355. Epub
2021 May 24. PMID: 34044315.
on cardiac, pulmonary and cutaneous toxicity in patients treated with adjuvant
radiotherapy for breast cancer. Breast Cancer. 2017 Jan;24(1):52-62. doi:
Available evidence on re-irradiation with stereotactic ablative radiotherapy
following high-dose previous thoracic radiotherapy for lung malignancies. Cancer
Treat Rev. 2015 Jun;41(6):511-8. doi: 10.1016/j.ctrv.2015.04.002. Epub 2015 Apr
Roviello F, Cinieri S, Donato V, De Luca R; NutriOnc Research Group. Clinical
nutrition in surgical oncology: Young AIOM-AIRO-SICO multidisciplinary national
survey on behalf of NutriOnc research group. Front Nutr. 2023 Apr 14;10:1045022.
doi: 10.3389/fnut.2023.1045022. PMID: 37125048; PMCID: PMC10140427.
Cancer Treatment. Am J Clin Oncol. 2023 Jan 1;46(1):1. doi:
Visani L, Baki M, Poggesi L, Bonomo P, Mangoni M, Desideri I, Pallotta S, Livi
comprehensive literature review to provide practical answers to frequently asked
Limatola V, Locatello LG, Mannelli G, Spinelli G, Guido C, Livi L. Acupuncture
for radiation-induced toxicity in head and neck squamous cell carcinoma: a
systematic review based on PICO criteria. Eur Arch Otorhinolaryngol. 2022
Apr;279(4):2083-2097. doi: 10.1007/s00405-021-07002-1. Epub 2021 Jul 31. PMID:
34331571; PMCID: PMC8930866.
Mangoni M, Scoccianti S, Simontacchi G, Francolini G, Meattini I, Caini S, Livi
treated with radiotherapy and cetuximab: A systematic review. Crit Rev Oncol
Oct 31. PMID: 29198343.
L, Buglione M, Caravatta L, D'Angelillo RM, Filippi AR, Fiore M, Genovesi D,
Greco C, Livi L, Magrini SM, Marvaso G, Mazzola R, Meattini I, Merlotti A,
Palumbo I, Pergolizzi S, Ramella S, Ricardi U, Russi E, Trovò M, Sindoni A,
Valentini V, Corvò R. Combination of novel systemic agents and radiotherapy for
solid tumors - part I: An AIRO (Italian association of radiotherapy and clinical
oncology) overview focused on treatment efficacy. Crit Rev Oncol Hematol. 2019
Feb;134:87-103. doi: 10.1016/j.critrevonc.2018.11.005. Epub 2018 Dec 1. PMID:
Garlatti P, Simontacchi G, Francolini G, Bonomo P, Wandael Y, Desideri I, Ricci
R, Giansanti D, Scotti V, Livi L. Recent Advances and Current Challenges in
Stereotactic Body Radiotherapy for Ultra-Central Lung Tumors. Cancers (Basel).
2024 Dec 11;16(24):4135. doi: 10.3390/cancers16244135. PMID: 39766035; PMCID:
time is there! Breast. 2018 Apr;38:98-100. doi: 10.1016/j.breast.2017.12.014.
Epub 2018 Jan 4. PMID: 29289822.
Pezzulla D, Caramia G, Dominici L, Maragna V, Teriaca MA, Bottero M, Livi L.
Stereotactic body radiation therapy (SBRT) on renal cell carcinoma, an overview
of technical aspects, biological rationale and current literature. Crit Rev
Oncol Hematol. 2018 Nov;131:24-29. doi: 10.1016/j.critrevonc.2018.08.010. Epub
2018 Aug 28. PMID: 30293702.
Intelligence: Future Perspectives. Adv Neurobiol. 2024;36:983-997. doi:
98: Mangoni M, Livi L, Biti G, Di Cataldo V, Capaccioli N, Castier Y, Loriot Y,
Mordant P, Deutsch E. Stem cell tracking: toward clinical application in
oncology? Tumori. 2012 Sep-Oct;98(5):535-42. doi: 10.1177/030089161209800501.
PMID: 23235746.
Aristei C, Genovesi D, Jereczek-Fossa BA, Morganti AG, Kovács G, Guinot JL,
Rembielak A, Greto D, Gambacorta MA, Valentini V, Donato V, Corvò R, Magrini SM,
Livi L; Consensus Conference Board. INTERACTS (INTErventional Radiotherapy
ACtive Teaching School) consensus conference on sarcoma interventional
radiotherapy (brachytherapy) endorsed by AIRO (Italian Association of
Radiotherapy and Clinical Oncology). J Contemp Brachytherapy. 2020
Aug;12(4):397-404. doi: 10.5114/jcb.2020.98120. Epub 2020 Aug 21. PMID:
33293980; PMCID: PMC7690224.
solid tumors - Part II: An AIRO (Italian association of radiotherapy and
clinical oncology) overview focused on treatment toxicity. Crit Rev Oncol
Nov 30. PMID: 30658887.
Amoroso D, Barni S, Bengala C, Guarneri V, Marchetti P, Martella F, Piovano P,
Vannini A, Desideri I, Tarquini R, Galanti G, Barletta G, Livi L. SAFE trial: an
ongoing randomized clinical study to assess the role of cardiotoxicity
prevention in breast cancer patients treated with anthracyclines with or without
2017 Mar 31. PMID: 28364270.
Stocchi G, Salvestrini V, Lancia A, Scartoni D, Giacomelli I, Sardaro A,
Carbonara R, Borghesi S, Aristei C, Livi L. Toxicity after moderately
hypofractionated versus conventionally fractionated prostate radiotherapy: A
systematic review and meta-analysis of the current literature. Crit Rev Oncol
Aug 3. PMID: 34352361.
Terziani F, Delli Paoli C, Olmetto E, Bonomo P, Livi L. Radiotherapy in the age
of cancer immunology: Current concepts and future developments. Crit Rev Oncol
Valzano M, Morelli I, Angelini L, Scotti V, Bonomo P, Greto D, Terziani F,
Becherini C, Visani L, Livi L. Use of an alfa-lipoic, Methylsulfonylmethane,
Boswellia serrata and Bromelain dietary supplement (OPERA®) for aromatase
inhibitors-related arthralgia management (AIA): a prospective phase II trial
(NCT04161833). Med Oncol. 2022 Jun 6;39(8):113. doi: 10.1007/s12032-022-01723-x.
PMID: 35666314.
F, Foglietta J, Cariello A, Ferro A, Picardo E, Mitidieri M, Sini V, Stani S,
Tonini G, Santini D, La Verde N, Gambaro AR, Grassadonia A, Tinari N, Garrone O,
Sarobba G, Livi L, Meattini I, D'Auria G, Vergati M, Gamucci T, Pistelli M,
Berardi R, Risi E, Giotta F, Lorusso V, Rinaldi L, Artale S, Cazzaniga ME,
Zustovich F, Cappuzzo F, Landi L, Torrisi R, Scagnoli S, Botticelli A,
Michelotti A, Fratini B, Saltarelli R, Paris I, Muratore M, Cassano A, Gianni L,
Gaspari V, Veltri EM, Zoratto F, Fiorio E, Fabbri MA, Mazzotta M, Ruggeri EM,
Pedersini R, Valerio MR, Filomeno L, Minelli M, Scavina P, Raffaele M, Astone A,
De Vita R, Pozzi M, Riccardi F, Greco F, Moscetti L, Giordano M, Maugeri-Saccà
M, Zennaro A, Botti C, Pelle F, Cappelli S, Cavicchi F, Vizza E, Sanguineti G,
Tomao F, Cortesi E, Marchetti P, Tomao S, Speranza I, Sperduti I, Ciliberto G,
Vici P. Adjuvant capecitabine in triple negative breast cancer patients with
residual disease after neoadjuvant treatment: real-world evidence from
<i>CaRe</i>, a multicentric, observational study. Front Oncol. 2023 May
16;13:1152123. doi: 10.3389/fonc.2023.1152123. PMID: 37260975; PMCID:
Becherini C, Livi L, Bonomo P. Impact of radiation dose on patient-reported
acute taste alteration in a prospective observational study cohort in head and
neck squamous cell cancer (HNSCC). Radiol Med. 2023 Dec;128(12):1571-1579. doi:
Mattioli C, Angelini L, Visani L, Scotti V, Livi L, Caini S, Bonomo P. Impact of
fosaprepitant in the prevention of nausea and emesis in head and neck cancer
patients undergoing cisplatin-based chemoradiation: a pilot prospective study
and a review of literature. Radiol Med. 2024 Mar;129(3):457-466. doi:
Beltrami G, Campanacci D, Scoccianti G, Capanna R, Mangoni M, Paiar F, Franchi
A, Biti G. Neoadjuvant treatment of soft tissue sarcoma. Radiol Med. 2014
Mar;119(3):195-200. doi: 10.1007/s11547-013-0331-6. Epub 2013 Nov 26. PMID:
Cipressi S, Biti G. Oral ibandronate in metastatic bone breast cancer: the
Florence University experience and a review of the literature. J Chemother. 2010
Feb;22(1):58-62. doi: 10.1179/joc.2010.22.1.58. PMID: 20227995.
J, Agresti B, Iermano C, Pasquetti EM, Bianchi S, Cataliotti L, Biti G.
Postmastectomy radiotherapy in breast cancer adjuvant treatment. Minerva Chir.
2010 Oct;65(5):527-36. PMID: 21081864.
ME, Valzano M, Francolini G, Sottili M, Santini C, Becherini C, Campanacci DA,
Mangoni M, Livi L. Radiosensitizing Effect of Trabectedin on Human Soft Tissue
Sarcoma Cells. Int J Mol Sci. 2022 Nov 18;23(22):14305. doi:
Scotti V, Matucci A, Mangoni M, Livi L, Bonomo P. Desensitization Protocol for
Cemiplimab-Related Infusion Reaction in Cutaneous Squamous Cell Carcinoma: A
Case Report and Literature Review. Curr Oncol. 2023 Jul 14;30(7):6699-6707. doi:
Mencarini J, Campolmi I, Gori L, Giovannoni L, Amato C, Livi L, Rasero L,
Fattirolli F, Marcucci R, Giusti B, Olivotto I, Tomassetti S, Lavorini F, Maggi
L, Annunziato F, Marchionni N, Zammarchi L, Bartoloni A. Infection with SARS-
CoV-2 Variants Is Associated with Different Long COVID Phenotypes. Viruses. 2022
Oct 27;14(11):2367. doi: 10.3390/v14112367. PMID: 36366465; PMCID: PMC9698829.
Pallotta S. Auto-planning for VMAT accelerated partial breast irradiation.
Radiother Oncol. 2019 Mar;132:85-92. doi: 10.1016/j.radonc.2018.11.006. Epub
2018 Dec 21. PMID: 30825975.
T, Desideri I, Livi L, Lapini A, Nicita G, Carini M, Biti G. Synchronous
bilateral testicular germ cell tumour: case report and review of the literature.
Klin Onkol. 2013;26(4):281-5. doi: 10.14735/amko2013281. PMID: 23961859.
Clin Oncol (R Coll Radiol). 2022 Jan;34(1):e84-e85. doi:
Franco P, Franzese C, Orlandi E, Livi L, Caini S. What is the prognostic impact
of FDG PET in locally advanced head and neck squamous cell carcinoma treated
with concomitant chemo-radiotherapy? A systematic review and meta-analysis. Eur
J Nucl Med Mol Imaging. 2018 Nov;45(12):2122-2138. doi:
C, Abdulcadir D, Vanzi E, Boeri C, Gabbrielli S, Lucci F, Sanchez L, Casella D,
Bernini M, Orzalesi L, Vezzosi V, Greto D, Mangoni M, Bianchi S, Livi L, Nori J.
Impact of molecular subtypes classification concordance between preoperative
core needle biopsy and surgical specimen on early breast cancer management:
Single-institution experience and review of published literature. Eur J Surg
Ingrosso G. Combining abiraterone and radiotherapy in metastatic castration-
resistant prostate cancer: a review of current evidence. Tumori. 2019
Aug;105(4):277-281. doi: 10.1177/0300891619839282. Epub 2019 Mar 25. PMID:
órgano-confinado: tratamiento con altas dosis de radioterapia (radioterapia de
intensidad modulada) [Organ-confined prostate cancer: treatment with high doses
of radioterapy (intensity modulated radiotherapy)]. Actas Urol Esp. 2007
Jun;31(6):611-6. Spanish. doi: 10.1016/s0210-4806(07)73697-5. PMID: 17896557.
Phase 3 Trial Experience and Future Perspectives. Am J Clin Oncol. 2023 Jan
1;46(1):10-15. doi: 10.1097/COC.0000000000000968. Epub 2022 Dec 6. PMID:
Morrone D, Nori Cucchiari J, Bianchi S, Livi L, Orzalesi L, Meattini I. B3
Breast Lesions: Positive Predictive Value and Follow-Up on a Large Single-
Institution Series. J Surg Res. 2024 Jul;299:366-373. doi:
study of plan complexity. Med Phys. 2021 Mar;48(3):942-952. doi:
Simontacchi G, Desideri I, Greto D, Valzano M, Serni S, Vaggelli L, Salvestrini
V, Visani L, Becherini C, Olmetto E, Franzese C, Baldaccini D, Scorsetti M,
Sollini M, Chiti A, Meattini I, Valicenti RK, Livi L. Early biochemical outcomes
following PSMA guided approach for bIoCHEmical relapse after prostatectomy-
PSICHE trial (NCT05022914): preliminary results. Clin Exp Metastasis. 2023
Apr;40(2):197-201. doi: 10.1007/s10585-023-10204-y. Epub 2023 Apr 3. PMID:
37012498; PMCID: PMC10113311.
M, Maragna V, Teriaca MA, Livi L. Radiotherapy in prostate cancer after kidney
transplant in 6 cases. Tumori. 2022 Aug;108(4):371-375. doi:
P, Minniti G, Livi L, Desideri I. Integrating nutritional status and
hematological biomarkers for enhanced prognosis prediction in glioma patients: A
systematic review. Clin Nutr ESPEN. 2025 Apr;66:269-280. doi:
Coppini R, Romei A, Marchi A, Morelli I, van Slegtenhorst MA, Palinkas ED, Livi
L, Michels M, Olivotto I. Cancer Treatment-Related Complications in Patients
With Hypertrophic Cardiomyopathy. Mayo Clin Proc. 2024 Feb;99(2):218-228. doi:
Guerini AE, Mazzola R, Cuccia F, Mariotti M, Salvestrini V, Garlatti P, Borghesi
S, Ingrosso G, Bellavita R, Aristei C, Desideri I, Livi L. Dose-escalated pelvic
radiotherapy for prostate cancer in definitive or postoperative setting. Radiol
PMID: 34850352.
Zambuto SG, Hoffman-Kim D. Cortical Spheroid Model for Studying the Effects of
Ischemic Brain Injury. In Vitro Model. 2023 Mar 29;2(1-2):25-41. doi:
Livi L. Preoperative single fraction breast radiotherapy: Intra-fraction
geometric uncertainties and dosimetric implications. Phys Med. 2023
Aug;112:102638. doi: 10.1016/j.ejmp.2023.102638. Epub 2023 Jul 11. PMID:
Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi G, Livi L.
Correction to: Impact of COVID-19 on patient-doctor interaction in a complex
radiation therapy facility. Support Care Cancer. 2022 Feb;30(2):1891-1892. doi:
Jun;29(6):2931-2937. doi: 10.1007/s00520-020-05793-3. PMID: 34750667; PMCID:
RA, Maccioni G, Giansanti D. Precision Metrics: A Narrative Review on Unlocking
the Power of KPIs in Radiology for Enhanced Precision Medicine. J Pers Med. 2024
Sep 10;14(9):963. doi: 10.3390/jpm14090963. PMID: 39338217; PMCID: PMC11433247.
Greto D, Baldazzi V, Simontacchi G, Meattini I, Livi L. Complete response in
metastatic renal cell carcinoma after radiotherapy and everolimus: a clinical
case and review of the literature. J Chemother. 2016 Oct;28(5):432-4. doi:
V, Desideri I, Marrazzo L, Wandael Y, Cornacchione P, Pallotta S, Giansanti D,
Ricci R, Livi L, Bonomo P. Open-Face Masks in Radiotherapy: Enhancing
Therapeutic Strategies for Head and Neck and Brain Cancer Patients-A
Comprehensive Scoping Review. Cancers (Basel). 2024 Aug 21;16(16):2899. doi:
Compagnucci A, Talamonti C, Raspanti D, Pertutti S, Di Cataldo V, Livi L,
Pallotta S. A semi-automatic planning technique for whole breast irradiation
with tangential IMRT fields. Phys Med. 2022 Jun;98:122-130. doi:
Bruni A, Russo D, Saldi S, Di Staso M, Francolini G, Lancia A, Marinelli L, Di
Muzio N, Aristei C, Livi L, Magrini SM, Ingrosso G. Radiotherapy at
oligoprogression for metastatic castration-resistant prostate cancer patients: a
multi-institutional analysis. Radiol Med. 2022 Jan;127(1):108-116. doi:
V, Elkhuizen PHM, Kirova Y, Rivera S. In Regard to Vaidya et al. Int J Radiat
Oncol Biol Phys. 2015 Aug 1;92(5):960-961. doi: 10.1016/j.ijrobp.2015.05.030.
Epub 2015 Jul 14. PMID: 26194670.
Castiglione F, Bonomo P, Meattini I, Greto D, Cappelli S, Di Brina L, Loi M,
Biti G, Livi L. A PPAR-gamma agonist protects from radiation-induced intestinal
M, Arrighi G, Barletta MT, De Maio E, Banchi M, Fini E, Guidi P, Frenzilli G,
Donati S, Giovannelli S, Tanganelli L, Salvadori B, Livi L, Meattini I, Pazzagli
I, Di Lieto M, Pistelli M, Casadei V, Ferro A, Cupini S, Orlandi F, Francesca D,
Lorenzini G, Barellini L, Falcone A, Cosimi A, Bocci G. A pharmacogenetic
interaction analysis of bevacizumab with paclitaxel in advanced breast cancer
Gandini S, Corso F, Ciccone LP, Zerella MA, Gentile P, Bianciardi F, Allegretta
S, Detti B, Desideri I, D'Angelillo RM, Masi L, Ingrosso G, Di Staso M, Mazzeo
E, Trippa F, Lohr F, Bruni A, Livi L. Stereotactic or conventional radiotherapy
for macroscopic prostate bed recurrence: a propensity score analysis. Radiol
PMID: 35247134; PMCID: PMC8897730.
Greto D, Desideri I, Vernaleone M, Francolini G, Livi L, Pallotta S. Clinical
validation of an automatic atlas-based segmentation tool for male pelvis CT
Epub 2022 Jan 22. PMID: 35064746; PMCID: PMC8906199.
Pelucchi S, Napoli G, Maniaci A, Cocuzza S, Vicini C. Conventional approaches
versus laser CO2 surgery in stapes surgery: a multicentre retrospective study.
Eur Arch Otorhinolaryngol. 2022 May;279(5):2321-2327. doi:
Mangoni M, Desideri I, Meattini I, Livi L. May Different Treatment Volumes and
Technical Approaches Have an Impact on Second Malignancies Risk? J Clin Oncol.
2021 Nov 20;39(33):3762-3763. doi: 10.1200/JCO.21.01790. Epub 2021 Sep 17. PMID:
I, Gori L, Rasero L, Fattirolli F, Olivotto I, Lavorini F, Marchionni N,
Zammarchi L, Bartoloni A; Careggi Post-acute COVID-19 Study Group. Clinical and
Laboratory Follow-up After Hospitalization for COVID-19 at an Italian Tertiary
Care Center. Open Forum Infect Dis. 2021 Feb 4;8(3):ofab049. doi:
Perigli G, Badii B, Vezzosi V, Simontacchi G, Livi L, Antonuzzo L, Maggi M,
Petrone L. Classic and Follicular Variant of Papillary Thyroid Microcarcinoma: 2
Different Phenotypes Beyond Tumor Size. J Endocr Soc. 2022 Oct 13;6(12):bvac157.
doi: 10.1210/jendso/bvac157. PMID: 36397778; PMCID: PMC9664971.
Triggiani L, Magrini SM, Ingrosso G, Aristei C, Franzese C, Scorsetti M, Alongi
oligometastatic prostate cancer: a multi-institutional study. Clin Exp
Mar 9. PMID: 35266063.
Placido S, Del Mastro L, Guarneri V, Generali D, Livi L, Lorusso V, Montemurro
F, Puglisi F, Vigneri P, Zambelli A, Arpino G. Controversial topics in
metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi
PMID: 36158652; PMCID: PMC9501706.
radiotherapy an effective treatment in metastatic lung cancer with
oligoprogressive disease? Acta Oncol. 2023 Mar;62(3):298-304. doi:
B, Greto D, Meattini I, Simontacchi G, Loi M, Scartoni D, Furfaro I, Pallotta S,
Livi L. Protective Effect of Leuprorelin on Radiation-induced Intestinal
Simontacchi G, Mangoni M, Paiar F, Meattini I, Scoccianti S, Santoro G, Valente
S, Gensini GF, Livi L. Stereotactic body radiotherapy with CyberKnife for
cardiac malignancies. Tumori. 2015 May-Jun;101(3):294-7. doi:
IEEE Trans Neural Netw Learn Syst. 2017 Dec;28(12):2846-2858. doi:
Pierossi N, Scotti V, Livi L, Bonomo P. The impact of patient preference in the
treatment algorithm for recurrent/metastatic head and neck squamous cell
Epub 2022 Jun 25. PMID: 35752659; PMCID: PMC9349154.
Ganovelli M, Morelli I, Romei A, Livi L, Bonomo P. Clinical outcome of nivolumab
in older and frail patients with recurrent/metastatic head and neck squamous
cell carcinoma. J Geriatr Oncol. 2023 Jan;14(1):101380. doi:
Saieva C, Del Bene MR, Pilato G, Desideri I, Arilli C, Paoletti L, Russo S,
Scoccianti S, Martella F, Francolini G, Simontacchi G, Nori Cucchiari J,
Pellegrini R, Livi L, Pallotta S. Subclinical cardiac damage monitoring in
breast cancer patients treated with an anthracycline-based chemotherapy
receiving left-sided breast radiation therapy: subgroup analysis from a phase 3
Epub 2024 Oct 22. PMID: 39436588.
dimensional traction forces of Schwann cells on compliant substrates. J R Soc
24872498; PMCID: PMC4208357.
Aquilano M, Greto D, Bonomo P, Meattini I, Scotti V, Scoccianti S, Simontacchi
G, Livi L. Impact of COVID-19 on workload burden of a complex radiotherapy
Epub 2021 Mar 1. PMID: 33646520; PMCID: PMC7917169.
Cinieri S, Rossetti S, De Placido S, Airoldi M, Galli L, Gasparro D, Ludovico
GM, Guglielmini PF, Carella C, Nova P, Aglietta M, Schips L, Beccaglia P,
Sciarra A, Livi L, Santini D; ABItude Study Group. Real-world experience of
abiraterone acetate plus prednisone in chemotherapy-naive patients with
metastatic castration-resistant prostate cancer: long-term results of the
prospective ABItude study. ESMO Open. 2022 Apr;7(2):100431. doi:
E, Salvestrini V, Bellini C, Masi L, Doro R, Di Naro F, Loi M, Salvatore G,
Simontacchi G, Greto D, Bernini M, Nori J, Orzalesi L, Bianchi S, Mangoni M,
Livi L. Preoperative robotic radiosurgery for early breast cancer: Results of
the phase II ROCK trial (NCT03520894). Clin Transl Radiat Oncol. 2022 Sep
22;37:94-100. doi: 10.1016/j.ctro.2022.09.004. PMID: 36177053; PMCID:
Salvestrini V, Scoccimarro E, Valzano M, Cerbai C, Desideri I, Bernini M,
Orzalesi L, Nori J, Bianchi S, Morandi A, Meattini I. Safety of CDK4/6
inhibitors and concomitant radiation therapy in patients affected by metastatic
breast cancer. Radiother Oncol. 2022 Dec;177:40-45. doi:
Casati M, Chilà D, Compagnucci A, Talamonti C, Zani M, Livi L, Pallotta S. Fully
automated volumetric modulated arc therapy technique for radiation therapy of
locally advanced breast cancer. Radiat Oncol. 2023 Oct 30;18(1):176. doi:
Bianchi S, Livi L, Nori J. Role of core needle biopsy in primary breast
Epub 2017 May 16. PMID: 28510806.
Franceschini D, Di Cataldo V, Di Brina L, Baki M, Simontacchi G, Meattini I,
Carini M, Serni S, Nicita G, Livi L. Cyberknife treatment for low and
intermediate risk prostate cancer. Cancer Invest. 2015 May;33(5):188-92. doi:
Hemmatazad H, Mayinger M, Peulen H, Verbeke L, Ramella S, Castro P, Tsoutsou P,
Stellamans K, Shaukat A, Orazem M, Jeene P, Braam P, Verkooijen H, Simek IM,
Alongi F, Clementel E, Fortpied C, Machingura A, Boakye Oppong F, Guckenberger
M, Ost P. Health-related quality of life in men with oligometastatic prostate
cancer following metastases-directed stereotactic body radiotherapy: Real-world
data from the E<sup>2</sup>-RADIatE OligoCare cohort. Clin Transl Radiat Oncol.
2023 Dec 29;45:100715. doi: 10.1016/j.ctro.2023.100715. PMID: 38274388; PMCID:
Bruni A, Ingrosso G, D'angelillo RM, Tagliaferri L, Augugliaro M, Triggiani L,
Parisi S, Timon G, Arcidiacono F, Marvaso G, Jereczek-Fossa BA, Lancia A,
Franzese C, Alongi F, Simontacchi G, Greto D, Bonomo P, Loi M, Frosini G,
Burchini L, Desideri I, Meattini I, Valicenti RK, Livi L. Impact of stereotactic
body radiotherapy after progression in castrate resistant prostate cancer
patients undergoing first line abiraterone treatment. A subgroup analysis from
ARTO trial (NCT03449719). Prostate Cancer Prostatic Dis. 2025 Feb 19. doi:
Becherini C, Salvestrini V, Visani L, Nori Cucchiari J, De Benedetto D, Di Naro
F, Bicchierai G, Bellini C, Bianchi S, Orzalesi L, Livi L, Meattini I. Pre-
pectoral breast reconstruction with tissue expander entirely covered by
acellular dermal matrix: feasibility, safety and histological features resulting
from the first 64 procedures. Gland Surg. 2024 Mar 27;13(3):297-306. doi:
R, Arcangeli S, Vagge S, Russi E, Alongi F, Livi L, Buglione M. Letter to the
Editor regarding ESTRO-ASTRO guidelines on lung cancer radiotherapy during
COVID-19 pandemic. Radiother Oncol. 2020 Jun;147:229-230. doi:
investigate recurrent neural network dynamics. Sci Rep. 2017 Mar 10;7:44037.
doi: 10.1038/srep44037. PMID: 28281563; PMCID: PMC5345088.
Orzalesi L, Sanchez LJ, Susini T, Vezzosi V, Nori J. Radial scar without
associated atypical epithelial proliferation on image-guided 14-gauge needle
core biopsy: analysis of 49 cases from a single-centre and review of the
Epub 2011 Sep 23. PMID: 21944431.
management scenario: another step forward? J Thorac Dis. 2016
Oct;8(10):E1361-E1363. doi: 10.21037/jtd.2016.10.24. PMID: 27867628; PMCID:
Fiorentino A, Spoto R, Poortmans P, Aristei C, Livi L. The Italian Association
for Radiotherapy and Clinical Oncology (AIRO) position statements for
postoperative breast cancer radiation therapy volume, dose, and fractionation.
Radiol Med. 2022 Dec;127(12):1407-1411. doi: 10.1007/s11547-022-01563-9. Epub
2022 Oct 6. PMID: 36201098; PMCID: PMC9747865.
Impact of COVID-19 on patient-doctor interaction in a complex radiation therapy
2022 Feb;30(2):1891-1892. doi: 10.1007/s00520-021-06665-0. PMID: 33006676;
PMCID: PMC7531068.
Lorenzini G, Isca C, Fontana A, Livi L, Piacentini F, Fogli S, De Giorgi U,
Danesi R. Reply to comments on: Drug-drug interactions between palbociclib and
proton pump inhibitors may significantly affect clinical outcome of metastatic
breast cancer patients. ESMO Open. 2022 Feb;7(1):100381. doi:
Giorgi, et al. Nivolumab in Combination with Stereotactic Body Radiotherapy in
Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase
II NIVES Study. Eur Urol. 2022;81:274-82. Eur Urol. 2022 Apr;81(4):e98-e99. doi:
Desideri I, Meattini I, Mangoni M, Livi L. Killing two birds with a stone: how
to maximise benefit from metastasis-directed therapy and modern systemic
treatment in oligometastatic hormone sensitive prostate cancer. Clin Exp
Oct 15. PMID: 36242700.
Marrazzo L. Partial breast irradiation for ductal carcinoma in situ: The
Goldilocks principle? Breast J. 2018 Nov;24(6):1118-1119. doi:
Mattina S, Borghetti P, Magrini SM, Nicosia L, Alongi F, Ghirardelli P,
Vavassori V, Allegra AG, Aquilano M, Scoccimarro E, Peruzzi A, Pastina P, Visani
L, Desideri I, Serni S, Meattini I, Livi L. Impact of stereotactic body
radiotherapy vs palliative radiotherapy on oncologic outcomes of patients with
metastatic kidney cancer concomitantly treated with immune checkpoint
inhibitors: a preliminary, multicentre experience. Clin Transl Oncol. 2022
Oct;24(10):2039-2043. doi: 10.1007/s12094-022-02844-5. Epub 2022 Jun 23. PMID:
35739349; PMCID: PMC9418086.
Becherini C, Meattini I. Core needle biopsy for the assessment of unilateral
male breast lesions. Eur J Surg Oncol. 2017 Apr;43(4):680-682. doi:
letrozole and concomitant palliative radiotherapy for metastatic breast cancer.
PMID: 30118901.
I, Lodge N, Meldolesi E, Simontacchi G, Piperno G, Galardi A, Scoccianti S, Biti
GP, Harmer C. Uterine sarcoma: twenty-seven years of experience. Int J Radiat
Oncol Biol Phys. 2003 Dec 1;57(5):1366-73. doi: 10.1016/s0360-3016(03)00750-8.
PMID: 14630275.
Salvestrini V, Ciccone LP, Stocchi G, Meattini I, Francolini G, Mangoni M, Livi
in a humanized mouse model of breast cancer. Clin Transl Oncol. 2022
Jul;24(7):1395-1402. doi: 10.1007/s12094-022-02785-z. Epub 2022 Feb 25. PMID:
L, Arcara C, Moretti G, Gunnellini M, Coltelli L, Verderame F, Livi L, Sanna G,
Grasso D, Abbinante G, Ragni F. Real-World Clinical Outcomes of Ribociclib in
Combination with a Non-Steroidal Aromatase Inhibitor and a Luteinizing Hormone-
Releasing Hormone Agonist in Premenopausal HR+/HER2- Advanced Breast Cancer
Patients: An Italian Managed Access Program. Curr Oncol. 2022 Sep
17;29(9):6635-6641. doi: 10.3390/curroncol29090521. PMID: 36135090; PMCID:
Bellini C, Greto D, Desideri I, Livi L. Bevacizumab in recurrent high-grade
glioma: a single institution retrospective analysis on 92 patients. Radiol Med.
2021 Sep;126(9):1249-1254. doi: 10.1007/s11547-021-01381-5. Epub 2021 Jun 3.
PMID: 34081269; PMCID: PMC8370943.
Tsaneva-Atanasova K. Data-Driven Prediction of Freezing of Gait Events From
Stepping Data. Front Med Technol. 2020 Nov 20;2:581264. doi:
Becherini C, Garlatti P, Delli Paoli C, Dominici L, Gerini C, Scoccianti S,
Bonomo P, Silvano A, Beltrami G, Campanacci D, Livi L. Enhancement of Soft
Tissue Sarcoma Cell Radiosensitivity by Poly(ADP-ribose) Polymerase-1
2018 Aug 1. PMID: 30067444.
JR, Darling EM, Kauer JA, Hoffman-Kim D. Three-Dimensional Neural Spheroid
Culture: An In Vitro Model for Cortical Studies. Tissue Eng Part C Methods. 2015
Dec;21(12):1274-83. doi: 10.1089/ten.TEC.2015.0135. Epub 2015 Oct 6. PMID:
26414693; PMCID: PMC4663656.
Livi L, Simontacchi G. ADAM: A breathing phantom for lung SBRT quality
2017 Jul 20. PMID: 28736284.
Francolini G, Guerrieri B, Livi L. Radiotherapy is effective in the management
of rare penile metastases: Two case reports. Cancer Radiother. 2021
Jul;25(5):480-483. doi: 10.1016/j.canrad.2021.03.004. Epub 2021 Apr 22. PMID:
Bonomo P, Meattini I, Greto D, Loi M, Francolini G, Perna M, Grassi R, Biti G,
Livi L. Peroxisome proliferator activated receptor-gamma stimulation for
prevention of 5-fluorouracil-induced oral mucositis in mice. Head Neck. 2018
Mar;40(3):577-583. doi: 10.1002/hed.25017. Epub 2017 Nov 20. PMID: 29155481.
Simontacchi G, Morelli I, Burchini L, Allegra AG, Frosini G, Ganovelli M,
Salvestrini V, Olmetto E, Visani L, Becherini C, Valzano M, Carnevale MG, Roghi
M, Serni S, Mattioli C, Desideri I, Livi L. Three Months' PSA and Toxicity from
a Prospective Trial Investigating STereotactic sAlvage Radiotherapy for
Macroscopic Prostate Bed Recurrence after Prostatectomy-STARR (NCT05455736).
Cancers (Basel). 2023 Feb 3;15(3):992. doi: 10.3390/cancers15030992. PMID:
36765948; PMCID: PMC9913280.
L, Livi L, Marrazzo L, Pallotta S, Retico A, Sardi I, Talamonti C. Radiomic- and
dosiomic-based clustering development for radio-induced neurotoxicity in
pediatric medulloblastoma. Childs Nerv Syst. 2024 Aug;40(8):2301-2310. doi:
Berardi R, Livi L, Ficorella C, Natoli C, Cortesi E, Generali D, La Verde N,
Cassano A, Bria E, Moscetti L, Michelotti A, Adamo V, Zamagni C, Tonini G, Sergi
D, Marinelli D, Paoletti G, Tomao S, Botticelli A, Marchetti P, Tinari N,
Grassadonia A, Valerio MR, Mirabelli R, Fabbri MA, D'Ostilio N, Veltri E, Corsi
D, Garrone O, Paris I, Sarobba G, Meattini I, Pistelli M, Giotta F, Lorusso V,
Garufi C, Russo A, Cazzaniga M, Del Medico P, Roselli M, Vaccaro A, Perracchio
L, di Benedetto A, Daralioti T, Sperduti I, De Maria R, Di Leo A, Sanguineti G,
Ciliberto G, Vici P. The prognostic relevance of HER2-positivity gain in
metastatic breast cancer in the ChangeHER trial. Sci Rep. 2021 Jul
2;11(1):13770. doi: 10.1038/s41598-021-92774-z. PMID: 34215766; PMCID:
Brugia M, Pimpinelli N, Antonuzzo L, Mini E, Livi L, Maggi M, Peri A. Endocrine-
related adverse events in a large series of cancer patients treated with anti-
PD1 therapy. Endocrine. 2021 Oct;74(1):172-179. doi: 10.1007/s12020-021-02750-w.
Epub 2021 May 25. PMID: 34036513; PMCID: PMC8440282.
Russo D, Bruni A, Francolini G, Lancia A, Marinelli L, Di Muzio N, Livi L,
Magrini SM, Maranzano E, Musio D, Aristei C, Valeriani M. Stereotactic ablative
radiotherapy in castration-resistant prostate cancer patients with
oligoprogression during androgen receptor-targeted therapy. Clin Transl Oncol.
2021 Aug;23(8):1577-1584. doi: 10.1007/s12094-021-02553-5. Epub 2021 Jan 25.
PMID: 33495981.
Franceschini D, Di Brina L, Baki M, Simontacchi G, Meattini I, Carini M, Serni
S, Nicita G, Livi L. CyberKnife stereotactic radiotherapy for isolated
recurrence in the prostatic bed. World J Urol. 2016 Mar;34(3):311-7. doi:
I, Livi L, Simontacchi G, De Luca Cardillo C, Bendinelli B, Bastiani P, Mangoni
M, Agresti B, Biti G. Vinorelbine-based chemo-radiotherapy in non-small cell
lung cancer. Tumori. 2012 Jul-Aug;98(4):464-70. doi: 10.1177/030089161209800411.
PMID: 23052163.
Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J,
Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C,
Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo
S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. Adjuvant anastrozole versus
exemestane versus letrozole, upfront or after 2 years of tamoxifen, in
endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
Lancet Oncol. 2018 Apr;19(4):474-485. doi: 10.1016/S1470-2045(18)30116-5. Epub
2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184. doi:
Greto D, Desideri I, Vernaleone M, Francolini G, Livi L, Pallotta S.
Methodological approach to create an atlas using a commercial auto-contouring
Zerella MA, Gentile P, Bianciardi F, Allegretta S, Detti B, Masi L, Lo Russo M,
Livi L. Stereotactic radiotherapy for prostate bed recurrence after
prostatectomy, a multicentric series. BJU Int. 2020 Mar;125(3):417-425. doi:
chemo-radiotherapy in patients with locally advanced rectal cancer. Radiat
PMCID: PMC9052564.
CE, Mazza E, Franzese C, Biti G. Isolated chest wall implantation of non-small
cell lung cancer after fine-needle aspiration: a case report and review of the
L, Verrillo F, Bartoloni A, Marcucci R, Lavorini F, Fumagalli S, Ungar A,
Olivotto I, Rasero L, Fattirolli F, Marchionni N; AOU Careggi COVID-19 Follow-up
study Group. Factors associated with persistence of symptoms 1 year after
COVID-19: A longitudinal, prospective phone-based interview follow-up cohort
Epub 2021 Dec 7. PMID: 34903448; PMCID: PMC8648678.
Triggiani L, La Mattina S, D'Angelillo RM, Demofonti C, Mazzola R, Cuccia F,
Alongi F, Aquilano M, Allegra AG, Ciccone LP, Burchini L, Salvestrini V, Morelli
I, Frosini G, Desideri I, Livi L. Pattern of Recurrence After Stereotactic
Radiotherapy in Prostate Cancer Patients With Nodal Pelvic Relapse. A Multi-
Institutional Retrospective Analysis. Clin Oncol (R Coll Radiol). 2022
Jan;34(1):57-62. doi: 10.1016/j.clon.2021.09.014. Epub 2021 Sep 29. PMID:
Caprara L, Bertini N, Lorenzetti V, Olmetto E, Becherini C, Visani L,
Salvestrini V, Simontacchi G, Greto D, Bonomo P, Doro R, Masi L, Desideri I,
Meattini I, Serni S, Livi L. Stereotactic reirradiation with
Cyberknife<sup>R</sup> for locally recurrent prostate cancer, long-term toxicity
and clinical outcomes from a monocentric cohort. Radiol Med. 2023
Dec;128(12):1580-1588. doi: 10.1007/s11547-023-01721-7. Epub 2023 Sep 20. PMID:
L, Chioffi F, Della Puppa A, Maccari M, Cavallin F, Coppola M, Pittaro A, Rudà
R, Livi L, Lombardi G. Association between thyroid function and regorafenib
efficacy in patients with relapsed wild-type IDH glioblastoma: a large
multicenter study. J Neurooncol. 2023 Jun;163(2):377-383. doi:
Bruni A, Borghesi S, Fondelli S, Carfagno T, Santini R, Santoni R, Trodella LE,
Livi L. Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who
Progressed During Abiraterone Therapy. Anticancer Res. 2017 Jul;37(7):3717-3722.
doi: 10.21873/anticanres.11744. PMID: 28668865.
G, Di Brina L, Meattini I, Livi L. BRCA mutation in breast cancer patients:
Prognostic impact and implications on clinical management. Breast J. 2018
Nov;24(6):1019-1023. doi: 10.1111/tbj.13100. Epub 2018 Jul 31. PMID: 30066348.
"Combining Adjuvant Radiotherapy With Capecitabine in Chemotherapy-resistant
Breast Cancer: Feasibility, Safety, and Toxicity". Clin Breast Cancer. 2020
Oct;20(5):e623-e624. doi: 10.1016/j.clbc.2020.04.014. Epub 2020 May 6. PMID:
Ability to Climb a Tree? A Call for Novel Endpoints in the Appraisal of Ablative
Local Treatments of Oligometastatic Cancer. Oncologist. 2021
Jun;26(6):e1085-e1086. doi: 10.1002/onco.13747. Epub 2021 Apr 9. PMID: 33686724;
PMCID: PMC8176969.
Meattini I, Livi L. Integrating stereotactic body radiation therapy (SBRT) and
systemic treatments in oligoprogressive prostate cancer: new evidence from the
Benedetto D, Francolini G, Bianchi S, Vezzosi V, Sanchez L, Susini T, Orzalesi
L, Meattini I, Livi L, Miele V. Stereotactic vacuum-assisted breast biopsy:
Comparison between 11- and 8-gauge needles. Eur J Surg Oncol. 2017
Dec;43(12):2257-2260. doi: 10.1016/j.ejso.2017.07.011. Epub 2017 Oct 6. PMID:
Franceschini D, Di Brina L, Bakhi M, Simontacchi G, Meattini I, Livi L.
Stereotactic radiotherapy for isolated nodal recurrence of prostate cancer.
World J Urol. 2015 Aug;33(8):1197-203. doi: 10.1007/s00345-014-1427-x. Epub 2014
Oct 24. PMID: 25342516.
Marchetti P, Anselmi E, Tomao S, Giordano A, Ficorella C, Cannita K, Livi L,
Meattini I, Mauri M, Greco F, Veltri EM, Michelotti A, Moscetti L, Giotta F,
Lorusso V, Paris I, Tomao F, Santini D, Tonini G, Villa A, Gebbia V, Gamucci T,
Ciliberto G, Sperduti I, Mazzotta M, Barba M, Vici P. Second-line Eribulin in
Triple Negative Metastatic Breast Cancer patients. Multicentre Retrospective
Study: The TETRIS Trial. Int J Med Sci. 2021 Mar 27;18(10):2245-2250. doi:
Lucidi S, Cerbai C, Ciccone LP, Salvestrini V, Stocchi G, Guerrieri B, Visani L,
Loi M, Desideri I, Mangoni M, Meattini I, Livi L. Study protocol and preliminary
results from a mono-centric cohort within a trial testing stereotactic body
radiotherapy and abiraterone (ARTO-NCT03449719). Radiol Med. 2022
Aug;127(8):912-918. doi: 10.1007/s11547-022-01511-7. Epub 2022 Jun 28. PMID:
35763249; PMCID: PMC9349091.
L, Orzalesi L. Selective Denervation of Pectoralis Major Muscle Improves
Cosmetic Outcome and Quality of Life in Retro-Pectoral Implant Based Breast
B, Greto D, Desideri I, Livi L. Single-Fraction Stereotactic Body Radiotherapy
for Oligometastatic Lymph Node Relapse in Prostate Cancer. Oncol Res Treat.
2018;41(11):703-705. doi: 10.1159/000491605. Epub 2018 Oct 13. PMID: 30317236.
L, Masi L. Performance assessment of a new optimization system for robotic SBRT
MLC-based plans. Phys Med. 2020 Mar;71:31-38. doi: 10.1016/j.ejmp.2020.02.009.
Epub 2020 Feb 20. PMID: 32088563.
Salvestrini V, Scoccianti S, Greto D, Bonomo P, Pecchioli G, Bordi L, Della
Puppa A, Francolini G, Meattini I, Livi L. Outcome and prognostic factors for
older patients undergoing radiosurgery for brain metastases. J Geriatr Oncol.
2020 Sep;11(7):1103-1107. doi: 10.1016/j.jgo.2020.03.009. Epub 2020 Apr 4. PMID:
Parente P, Almadori G, Ansarin M, Bacigalupo A, Baumeister P, Baujat B, Bossi P,
Cavalera E, Cercato MC, Dieleman F, Fakhry N, Ferraresi V, Gaino F, Galizia D,
Halamkova J, Halme E, Hardillo J, Hofauer B, Kinloch E, Livi L, Locati LD,
Mattheis S, Mercante G, Mirabile A, Molteni G, Orlandi E, Persio R, Sciallero S,
Smeele L, Tagliabue M, Valentini V, Van Harpen C, Westphalen CB, Botta L. The
observational clinical registry (cohort design) of the European Reference
Network on Rare Adult Solid Cancers: The protocol for the rare head and neck
Stucci S, Meattini I, D'Onofrio R, Lorenzini G, Biondani P, De Giorgi U, Porta
C, Livi L, Natalizio S, Fontana A, Giontella E, Angelini L, Fogli S, Danesi R.
Concomitant administration of proton pump inhibitors does not significantly
affect clinical outcomes in metastatic breast cancer patients treated with
2022 Oct 15. PMID: 36283134; PMCID: PMC9593796.
Ganovelli M, Salvestrini V, Stocchi G, Zani M, Palomba A, Livi L. Durvalumab
with cetuximab and radiotherapy for locally advanced squamous cell carcinoma of
the head and neck: A phase 1/2 trial. Radiother Oncol. 2022 Apr;169:64-70. doi:
Scoccimarro E, Bellini C, Aquilano M, Allegra AG, Peruzzi A, Guerrieri B,
Morelli I, Valzano M, Ciccone LP, Salvestrini V, Desideri I, Livi L.
Stereotactic Re-irradiation in Recurrent Prostate Cancer after Previous
Postoperative or Definitive Radiotherapy: Long-term Results after a Median
Follow-up of 4 Years. Clin Oncol (R Coll Radiol). 2022 Jan;34(1):50-56. doi:
Talamonti C, Livi L, Pallotta S. Automatic VMAT technique to treat glioblastoma:
A two years' experience. Phys Med. 2021 Oct;90:115-122. doi:
Rigo M, Mazzola R, Perna M, Scotti V, Fodor A, Iurato A, Pasqualetti F, Gadducci
G, Chiesa S, Niespolo RM, Bruni A, Alicino G, Frassinelli L, Borghetti P, Di
Marzo A, Ravasio A, De Bari B, Sepulcri M, Aiello D, Mortellaro G, Sangalli C,
Franceschini M, Montesi G, Aquilanti FM, Lunardi G, Valdagni R, Fazio I,
Scarzello G, Corti L, Vavassori V, Maranzano E, Magrini SM, Arcangeli S,
Gambacorta MA, Valentini V, Paiar F, Ramella S, Di Muzio NG, Livi L, Jereczek-
Fossa BA, Osti MF, Scorsetti M, Alongi F. A multicenter LArge retrospectIve
daTabase on the personalization of stereotactic ABlative radiotherapy use in
lung metastases from colon-rectal cancer: The LaIT-SABR study. Radiother Oncol.
2022 Jan;166:92-99. doi: 10.1016/j.radonc.2021.10.023. Epub 2021 Nov 5. PMID:
Stocchi G, Bellini C, Lorenzetti V, Sordi S, Nori J, De Benedetto D, Desideri I,
Bianchi S, Livi L, Orzalesi L. Pre-pectoral breast reconstruction: early and
long-term safety evaluation of 146 unselected cases of the early pre-pectoral
era of a single-institution, including cases with previous breast irradiation
and post-mastectomy radiation therapy. Breast Cancer. 2022 Mar;29(2):302-313.
doi: 10.1007/s12282-021-01314-0. Epub 2021 Nov 14. PMID: 34775540.
Salvianti F, Salvatore G, Sottili M, Santini C, Frosini G, Visani L, Burchini L,
Mattioli C, Allegra AG, Valzano M, Cerbai C, Aquilano M, Salvestrini V, Desideri
I, Mangoni M, Meattini I, Livi L. Prospective assessment of AR splice variant
and multi-biomarker expression on circulating tumor cells of mCRPC patients
undergoing androgen receptor targeted agents: interim analysis of PRIMERA trial
(NCT04188275). Med Oncol. 2022 Jun 10;39(8):119. doi:
G, Desideri I, Greto D, Valzano M, Roghi M, Serni S, Vaggelli L, Salvestrini V,
Visani L, Becherini C, Olmetto E, Franzese C, Baldaccini D, Scorsetti M, Sollini
M, Chiti A, Meattini I, Valicenti RK, Livi L. PSMA guided approach for
bIoCHEmical relapse after prostatectomy- (PSICHE) trial (NCT05022914). Detection
rate and treatment decision after 68Ga-PSMA PET/CT within a prospective study.
PMID: 37290915.
Peruzzi A, Salvestrini V, Visani L, Olmetto E, Becherini C, Allegra A, Burchini
L, Scotti V, Mangoni M, Meattini I, Desideri I, Livi L. Predictive factors for
tolerance to taxane based chemotherapy in older adults affected by metastatic
prostate cancer (ANCHISES-NCT05471427): A prospective observational trial
including patients with metastatic hormone sensitive and castrate resistant
prostate cancer treated with taxane chemotherapy. J Geriatr Oncol. 2023
Jan;14(1):101411. doi: 10.1016/j.jgo.2022.11.010. Epub 2022 Dec 8. PMID:
F, Lavorini F, Olivotto I, Fumagalli C, Zocchi C, Tassetti L, Gozzi L,
Marchionni N, Maggi M, Peri A; AOU Careggi COVID-19 Follow-up Study Group.
Relationship between hyponatremia at hospital admission and cardiopulmonary
profile at follow-up in patients with SARS-CoV-2 (COVID-19) infection. J
Endocrinol Invest. 2023 Mar;46(3):577-586. doi: 10.1007/s40618-022-01938-9. Epub
2022 Oct 25. PMID: 36284058; PMCID: PMC9595583.
Scotti V, Loi M, Detti B, Mangoni M, Agresti B, Baldazzi V, Greto D, Casella D,
Bernini M, Sanchez LJ, Orzalesi L, Nori J, Fambrini M, Bianchi S, Livi L. Safety
of eribulin mesylate and concomitant radiotherapy for metastatic breast cancer:
a single-center experience. Future Oncol. 2016 May;12(9):1117-24. doi:
Fusi F, Desideri I, Bonomo P, Livi L, Pallotta S. A multiparametric method to
assess the MIM deformable image registration algorithm. J Appl Clin Med Phys.
2019 Apr;20(4):75-82. doi: 10.1002/acm2.12564. Epub 2019 Mar 28. PMID: 30924286;
PMCID: PMC6448167.
Filippi AR; AIRO Giovani (Italian Association of Radiation Oncology-Young
Members Working Group). The "BUONGIORNO" project: burnout syndrome among young
Italian radiation oncologists. Cancer Invest. 2013 Oct;31(8):522-8. doi:
Cerbai C, Desideri I, Ribnikar D, Marinko T, Livi L, Meattini I. Cyclin-
Dependent Kinase 4/6 Inhibitors Combined With Radiotherapy for Patients With
Metastatic Breast Cancer. Clin Breast Cancer. 2020 Dec;20(6):495-502. doi:
Assessment in Blind Scuba Divers. Sultan Qaboos Univ Med J. 2015
Nov;15(4):e569-71. doi: 10.18295/squmj.2015.15.04.025. Epub 2015 Nov 23. PMID:
26629392; PMCID: PMC4664110.
G, Wandael Y, Barra A, Pallotta S, Ricci R, Livi L. Enhancing patient safety in
radiotherapy: Implementation of a customized electronic checklist for radiation
Aquilano M, Pinzani P, Salvianti F, Desideri I, Mariotti M, Garlatti P, Stocchi
G, Ciccone LP, Lucidi S, Salvatore G, Sottili M, Meattini I, Livi L. Prospective
assessment of AR splice variant and PSMA detection on circulating tumor cells of
mCRPC patients: preliminary analysis of patients enrolled in PRIMERA trial
(NCT04188275). Clin Exp Metastasis. 2021 Oct;38(5):451-458. doi:
Lambertini M, Miccinesi G, Russell N, Saieva C, Strnad V, Visani L, Kaidar-
Person O, Livi L. Exclusive endocrine therapy or partial breast irradiation for
women aged ≥70 years with luminal A-like early stage breast cancer (NCT04134598
- EUROPA): Proof of concept of a randomized controlled trial comparing health
related quality of life by patient reported outcome measures. J Geriatr Oncol.
2021 Mar;12(2):182-189. doi: 10.1016/j.jgo.2020.07.013. Epub 2020 Jul 29. PMID:
Cataldo V, Pasquetti EM, Furfaro I, Mancuso A, Simontacchi G, Livi L. Docetaxel
in castration-resistant prostate cancer: a single-centre experience. Cancer
Bonomo P, Mangoni M, Greto D, Nori J, Orzalesi L, Casella D, Simoncini R,
Fambrini M, Bianchi S, Livi L. Postmastectomy radiotherapy for locally advanced
breast cancer receiving neoadjuvant chemotherapy. Biomed Res Int.
2014;2014:719175. doi: 10.1155/2014/719175. Epub 2014 Jun 22. PMID: 25045694;
PMCID: PMC4090568.
Scoccianti S, Simontacchi G, Bianchi S, Cataliotti L, Biti G. Benefit of
radiation boost after whole-breast radiotherapy. Int J Radiat Oncol Biol Phys.
2009 Nov 15;75(4):1029-34. doi: 10.1016/j.ijrobp.2008.12.038. Epub 2009 Apr 22.
PMID: 19395193.
Irradiation in Breast Cancer: Time for Trials on the Basis of Tumor Biology. J
Clin Oncol. 2016 Aug 1;34(22):2672-3. doi: 10.1200/JCO.2016.66.4276. Epub 2016
May 23. PMID: 27217466.
Favuzza V, Cipressi S, Iermano C, Bonucci I, Loi M, Biti G. Cyberknife
stereotactic radiosurgery for the re-irradiation of brain lesions: a single-
centre experience. Radiol Med. 2014 Sep;119(9):721-6. doi:
D, Vezzosi V, Orzalesi L, Nori J, Livi L, Arcangeli A, Lastraioli E. hERG1
channel expression associates with molecular subtypes and prognosis in breast
30002601; PMCID: PMC6034270.
Defferrari C, Delmonte A, Finocchiaro G, Francini G, Gelsomino F, Giannarelli D,
Giordano M, Illiano A, Livi L, Martelli O, Natoli C, Puppo G, Ricevuto E, Roca
E, Turci D, Galetta D. Efficacy of nivolumab in pre-treated non-small-cell lung
cancer patients harbouring KRAS mutations. Br J Cancer. 2019 Jan;120(1):57-62.
doi: 10.1038/s41416-018-0234-3. Epub 2018 Oct 31. PMID: 30377342; PMCID:
L, Terziani F, Muntoni C, Lo Russo M, Loi M, Livi L. Stereotactic radiotherapy
in oligoprogressive and oligorecurrent urothelial cancer patients: A
retrospective experience. Cancer Treat Res Commun. 2019;19:100124. doi:
D, Francolini G, Becherini C, Livi L. Robotic stereotactic radiotherapy for
liver oligometastases from colorectal cancer: a single-center experience. Radiol
PMID: 31104277.
Franzese C, Cassani S, Greto D, Masoni T, Meattini I, Pallotta S, Passeri A,
Pupi A, Vanzi E, Biti G, Livi L. A PPAR-gamma agonist attenuates pulmonary
injury induced by irradiation in a murine model. Lung Cancer. 2015
Dec;90(3):405-9. doi: 10.1016/j.lungcan.2015.11.005. Epub 2015 Nov 7. PMID:
relapse in testicular germ cell tumors. Tumori. 2007 Sep-Oct;93(5):428-31. doi:
Castiglione F, Bonomo P, Meattini I, Greto D, Olmetto E, Terziani F, Becherini
C, Delli Paoli C, Trombetta L, Loi M, Biti G, Livi L. A PPAR gamma agonist
protects against oral mucositis induced by irradiation in a murine model. Oral
Fozza A, Taraborrelli M, Piperno G, Vanoni V, Sepulcri M, Trovò M, Nardone V,
Lattanzi E, Bou Selman S, Bertolini F, Franceschini D, Agustoni F, Jereczek-
Fossa BA, Magrini SM, Livi L, Lohr F, Filippi AR. Corrigendum: A Real-World,
Multicenter, Observational Retrospective Study of Durvalumab After Concomitant
or Sequential Chemoradiation for Unresectable Stage III Non-Small Cell Lung
Erratum for: Front Oncol. 2021 Sep 28;11:744956. doi: 10.3389/fonc.2021.744956.
PMID: 34869046; PMCID: PMC8637883.
G, Palomba A, Lorenzetti V, Cerbai C, Desideri I, Francolini G, Bonomo P,
Campanacci DA, Livi L. Stereotactic Body Radiotherapy in
Oligomestatic/Oligoprogressive Sarcoma: Safety and Effectiveness Beyond
Intrinsic Radiosensitivity. Cancer J. 2021 Nov-Dec 01;27(6):423-427. doi:
Mariotti M, Castellucci P, Fanti S, Filippi AR, Teriaca MA, Maragna V, Aristei
C, Mazzeo E, Livi L, Ingrosso G. Detection rate, pattern of relapse and
influence on therapeutic decision of PSMA PET/CT in patients affected by
biochemical recurrence after radical prostatectomy, a retrospective case series.
Clin Transl Oncol. 2021 Feb;23(2):364-371. doi: 10.1007/s12094-020-02427-2. Epub
2020 Jun 29. PMID: 32602076.
in Castration-Resistant Prostate Cancer: A Single-Centre Experience. Cancer
Erratum for: Cancer Invest. 2014 Nov;32(9):445-50. doi:
L, Deganello A. Head and neck reconstruction with pedicled flaps in the free
flap era. Acta Otorhinolaryngol Ital. 2016 Dec;36(6):459-468. doi:
Scotti V, Cecchini S, Nori J, Sanchez LJ, Orzalesi L, Paiar F, Biti G.
Paclitaxel and bevacizumab in first-line treatment for HER2-negative metastatic
breast cancer: single-center experience. Med Oncol. 2013 Mar;30(1):434. doi:
Stereotactic Body Radiation Therapy in the Management of Oligometastatic and
Oligoprogressive Bladder Cancer and Other Urothelial Malignancies. Clin Oncol (R
Coll Radiol). 2021 Jan;33(1):50-56. doi: 10.1016/j.clon.2020.07.008. Epub 2020
Jul 25. PMID: 32723486.
Danesi R. Drug-drug interactions between palbociclib and proton pump inhibitors
may significantly affect clinical outcome of metastatic breast cancer patients.
ESMO Open. 2021 Oct;6(5):100231. doi: 10.1016/j.esmoop.2021.100231. Epub 2021
Sep 9. PMID: 34509802; PMCID: PMC8441157.
biomimetic synthetic feeder layer supports the proliferation and self-renewal of
mouse embryonic stem cells. Acta Biomater. 2016 Jul 15;39:55-64. doi:
Scoccianti S, Desideri I, Livi L. A dosimetric comparison between CyberKnife and
tomotherapy treatment plans for single brain metastasis. Radiol Med. 2017
May;122(5):392-397. doi: 10.1007/s11547-017-0735-9. Epub 2017 Feb 15. PMID:
M, Compagnucci A, Livi L, Pallotta S. Automated planning through robust
templates and multicriterial optimization for lung VMAT SBRT of lung lesions. J
Appl Clin Med Phys. 2020 Jun;21(6):114-120. doi: 10.1002/acm2.12872. Epub 2020
Apr 10. PMID: 32275353; PMCID: PMC7324702.
Adenoid cystic carcinoma of the breast. The double face of an exocrine gland
G, Zaccaro L, Cunicella G, Fallico A, Cattaneo CG, Lisi R, Arcieri S, Albanese
CV, Tini P, Detti B, Di Cataldo V, Mangoni M, Francolini G, Migliara G, Livi L,
De Felice F, Minniti G, Gravina GL, Baccolini V, Marampon F. Significant
interruptions in radiotherapy during curative treatment for prostate cancer are
correlated with poorer oncological outcomes. Int J Radiat Biol. 2025 Mar 4:1-8.
doi: 10.1080/09553002.2025.2470202. Epub ahead of print. PMID: 40036266.
Baldazzi V, Mangoni M, Scoccianti S, Detti B, Simontacchi G, Nori J, Orzalesi L,
Sanchez L, Casella D, Bernini M, Fambrini M, Bianchi S, Livi L. Impact of age on
cytotoxic-induced ovarian failure in breast cancer treated with adjuvant
chemotherapy and triptorelin. Future Oncol. 2016 Mar;12(5):625-35. doi:
Livi L, Raugei G. Targeting LMW-PTP to sensitize melanoma cancer cells toward
chemo- and radiotherapy. Cancer Med. 2018 May;7(5):1933-1943. doi:
Furfaro I, Bonomo P, Simontacchi G, Livi L. Nutritional Supplement Based on
Zinc, Prebiotics, Probiotics and Vitamins to Prevent Radiation-related
Gastrointestinal Disorders. Anticancer Res. 2015 Oct;35(10):5687-92. PMID:
Mariotti M, Salvestrini V, Bertolini F, Vagge S, Taraborrelli M, Falcinelli L,
Taddeo A, Rossi R, Costantino G, Frassinelli L, Filippi AR, Greco C,
Franceschini D, Genovesi D, Lohr F, Magrini SM, Alongi F, Livi L, Bruni A. The
NIPRO Study: An Observational, Retrospective, Multicenter Study on the Safety of
the Radiotherapy and Immunotherapy Combination for Advanced-Stage NSCLC. Clin
Lung Cancer. 2021 Sep;22(5):e767-e773. doi: 10.1016/j.cllc.2021.02.005. Epub
2021 Feb 16. PMID: 33766477.
Cecchini S, Loi M, Desideri I, Bordi L, Bono P, Bonomo P, Meattini I, Detti B,
Livi L. Gamma Knife Radiosurgery in the management of single and multiple brain
D, Teriaca MA, Lucidi S, Visani L, Terziani F, Olmetto E, Becherini C, Bonomo P,
Francolini G, Campanacci DA, Scoccianti G, Livi L. Patterns of Care and Survival
in Elderly Patients With Locally Advanced Soft Tissue Sarcoma. Am J Clin Oncol.
2019 Oct;42(10):749-754. doi: 10.1097/COC.0000000000000594. PMID: 31503061.
Muntoni C, Delli Paoli C, Topulli J, Campanacci D, Beltrami G, Scoccianti G,
Bonomo P, Desideri I, Francolini G, Livi L. A matched cohort study of radio-
chemotherapy versus radiotherapy alone in soft tissue sarcoma patients. Radiol
PMID: 30209796.
Means of Recurrence Analysis. IEEE Trans Neural Netw Learn Syst. 2018
Feb;29(2):427-439. doi: 10.1109/TNNLS.2016.2630802. Epub 2016 Dec 2. PMID:
Airoldi M, Amoroso D, Coltelli L, Scotti V, Becherini C, Visani L, Salvestrini
V, Mariotti M, Pedani F, Bernini M, Sanchez L, Orzalesi L, Nori J, Bianchi S,
Olivotto I, Meattini I. Cardioprotective Strategy for Patients With
Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based
Chemotherapy: A Randomized Clinical Trial. JAMA Oncol. 2021 Oct
1;7(10):1544-1549. doi: 10.1001/jamaoncol.2021.3395. PMID: 34436523; PMCID:
L, Magrini SM, Salgarello M, Alongi F. Metastasis-directed Therapy (SBRT) Guided
by PET-CT <sup>18</sup>F-CHOLINE Versus PET-CT <sup>68</sup>Ga-PSMA in
Castration-sensitive Oligorecurrent Prostate Cancer: A Comparative Analysis of
Fossa BA, Magrini SM, Livi L, Lohr F, Filippi AR. A Real-World, Multicenter,
Observational Retrospective Study of Durvalumab After Concomitant or Sequential
Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer. Front
PMCID: PMC8507147.
Innocenti M, Capanna R, Roselli G, Scoccianti G, Livi L, Greto D, Muntoni C,
Baldi G, Tamburini A, Campanacci DA. Clinical features, prognostic factors and
outcome in a series of 29 extra-skeletal Ewing Sarcoma. Adequate margins and
surgery-radiotherapy association improve overall survival. J Orthop. 2020 Mar
25;21:236-239. doi: 10.1016/j.jor.2020.03.018. PMID: 32273664; PMCID:
Giudici F, Bartoloni A, Fattirolli F, Lavorini F, Olivotto I, Nannoni A.
Prevalence of nutritional risk and malnutrition during and after hospitalization
for COVID-19 infection: Preliminary results of a single-centre experience. Clin
Nutr ESPEN. 2021 Oct;45:351-355. doi: 10.1016/j.clnesp.2021.07.020. Epub 2021
Aug 2. PMID: 34620339; PMCID: PMC8327581.
Bertocci S, De Majo R, Gasperi C, Curion AS, Lastrucci L, Dominici L, Pallotta
S, Livi L, Caini S. Analysis of skin dose distribution for the prediction of
severe radiation dermatitis in head and neck squamous cell carcinoma patients
treated with concurrent chemo-radiotherapy. Head Neck. 2020 Feb;42(2):244-253.
doi: 10.1002/hed.25997. Epub 2019 Nov 4. PMID: 31682308.
Mangoni M, Bonucci I, Greto D, Masi L, Doro R, Marrazzo L, Biti G. Stereotactic
body radiotherapy for cardiac and paracardiac metastases: University of Florence
Epub 2013 May 28. PMID: 23716288.
Meattini I, Berardi R, Di Lisa FS, Natoli C, Pistelli M, Iezzi L, Risi E,
D'Ostilio N, Tomao S, Ficorella C, Cannita K, Riccardi F, Cassano A, Bria E,
Fabbri MA, Mazzotta M, Barchiesi G, Botticelli A, D'Auria G, Ceribelli A,
Michelotti A, Russo A, Salimbeni BT, Sarobba G, Giotta F, Paris I, Saltarelli R,
Marinelli D, Corsi D, Capomolla EM, Sini V, Moscetti L, Mentuccia L, Tonini G,
Raffaele M, Marchetti L, Minelli M, Ruggeri EM, Scavina P, Bacciu O, Salesi N,
Livi L, Tinari N, Grassadonia A, Fedele Scinto A, Rossi R, Valerio MR, Landucci
E, Stani S, Fratini B, Maugeri-Saccà M, De Tursi M, Maione A, Santini D, Orlandi
A, Lorusso V, Cortesi E, Sanguineti G, Pinnarò P, Cappuzzo F, Landi L, Botti C,
Tomao F, Cappelli S, Bon G, Pelle F, Cavicchi F, Fiorio E, Foglietta J, Scagnoli
S, Marchetti P, Ciliberto G, Vici P. PANHER study: a 20-year treatment outcome
analysis from a multicentre observational study of HER2-positive advanced breast
cancer patients from the real-world setting. Ther Adv Med Oncol. 2021 Nov
29;13:17588359211059873. doi: 10.1177/17588359211059873. PMID: 35173816; PMCID:
Matteucci P, Franceschini D, Mantovani C, Beltramo G, Pasqualetti F, Bruni A,
Tini P, Giudice E, Ciammella P, Merlotti A, Pedretti S, Trignani M, Krengli M,
Giaj-Levra N, Desideri I, Pecchioli G, Muto P, Maranzano E, Fariselli L,
Navarria P, Ricardi U, Scotti V, Livi L. Immunotherapy in association with
stereotactic radiotherapy for non-small cell lung cancer brain metastases:
results from a multicentric retrospective study on behalf of AIRO. Neuro Oncol.
2021 Oct 1;23(10):1750-1764. doi: 10.1093/neuonc/noab129. PMID: 34050669; PMCID:
Matrone F, Nicosia L, Timon G, Ognibene L, Vinciguerra A, Alongi F, Bortolus R,
Corti L, Ramella S, Magrini SM, Livi L, Jereczek-Fossa BA, Scorsetti M,
Arcangeli S. The role of stereotactic body radiation therapy and its integration
with systemic therapies in metastatic kidney cancer: a multicenter study on
behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology)
genitourinary study group. Clin Exp Metastasis. 2021 Dec;38(6):527-537. doi:
Pasinetti N, Lancellotta V, Giacobazzi P, La Rocca E, D'Angelo E, Lozza L, Livi
L, Meattini I, Scorsetti M. Comparing hypofractionated and conventionally
fractionated whole breast irradiation for patients with ductal carcinoma in situ
after breast conservation: a propensity score-matched analysis from a national
multicenter cohort (COBCG-02 study). J Cancer Res Clin Oncol. 2021
Jul;147(7):2069-2077. doi: 10.1007/s00432-020-03483-5. Epub 2021 Jan 2. PMID:
Roselli G, Scorianz M, Capanna R, Campanacci D. Myxoid Liposarcoma: Prognostic
Factors and Metastatic Pattern in a Series of 148 Patients Treated at a Single
289: Krasniqi E, Filomeno L, Arcuri T, Di Lisa FS, Astone A, Cutigni C,
Foglietta J, Nunzi M, Rossi R, Minelli M, Meattini I, Visani L, Scialino J, Livi
L, Moscetti L, Marchetti P, Botticelli A, Paris I, Pavese F, D'Angelo T, Sini V,
Stani S, Valerio MR, Grassadonia A, Tinari N, Mazzotta M, Vergati M, D'Auria G,
Gamucci T, D'Onofrio L, Gasparro S, Roselli A, Fulvi A, Ferretti G, Torchia A,
Giordano M, Greco F, Pantano F, Tonini G, Fabbri A, Bria E, Garufi G, Fiorio E,
Raffaele M, Pistelli M, Berardi R, Saltarelli R, Kayal R, Ferranti FR, Cannita
K, Irelli A, D'Ostilio N, De Rossi C, Palumbo R, Cariello A, Sanguineti G,
Calabrò F, Pizzuti L, Barba M, Botti C, Pelle F, Cappelli S, Cavicchi F, Puccica
I, Villanucci A, Sperduti I, Ciliberto G, Vici P. Tolerability and Preliminary
Outcomes of Adjuvant T-DM1 in HER2-Positive Breast Cancer After Neoadjuvant
Therapy: The ATD Study. Cancers (Basel). 2024 Dec 7;16(23):4104. doi:
Garlatti P, Massi D, Gallo O, Livi L. Re-irradiation for oligoprogression under
Nivolumab in recurrent head and neck squamous cell carcinoma: A case report.
Clin Transl Radiat Oncol. 2020 Apr 17;23:16-19. doi: 10.1016/j.ctro.2020.04.007.
PMID: 32368625; PMCID: PMC7186263.
Agresti B, Mazzini C, Livi L. A rare case of non-small cell lung cancer
choroidal metastasis responding to ALK tyrosine kinase inhibitors. Anticancer
breast cancer? Lancet Oncol. 2015 Feb;16(2):e53. doi:
D, Mangoni M, Nori J, Orzalesi L, Fambrini M, Bianchi S, Livi L. Impact of
sentinel node tumor burden on outcome of invasive breast cancer patients. Eur J
Surg Oncol. 2014 Oct;40(10):1195-202. doi: 10.1016/j.ejso.2014.08.471. Epub 2014
Aug 20. PMID: 25179162.
Meattini I, Cecchini S, Mangoni M, Doro R, Iermano C, Bonucci I, Livi L, Biti G.
Clinical outcome of stereotactic body radiotherapy for abdominal lymph node
PMID: 24362866.
R, Weltens C, Navarria P, Belkacemi Y, Lopez-Guerra J, Livi L, Baumert BG,
Vieites B, Limon D, Kurman N, Ko K, Yu JB, Chiang V, Poortmans P, Zagar T.
Discrepancies between biomarkers of primary breast cancer and subsequent brain
metastases: an international multicenter study. Breast Cancer Res Treat. 2018
Jan;167(2):479-483. doi: 10.1007/s10549-017-4526-8. Epub 2017 Oct 3. PMID:
Greto D, Francolini G, Carfora V, Pezzulla D, Perna M, Carta GA, Livi L. Robotic
Stereotactic Retreatment for Biochemical Control in Previously Irradiated
Patients Affected by Recurrent Prostate Cancer. Clin Oncol (R Coll Radiol). 2018
Feb;30(2):93-100. doi: 10.1016/j.clon.2017.11.007. Epub 2017 Dec 6. PMID:
C, Cassani S, Paiar F, Di Cataldo V, Nori J, Jose Sanchez L, Bianchi S,
Cataliotti L, Biti G. Concomitant adjuvant chemo-radiation therapy with
anthracycline-based regimens in breast cancer: a single centre experience.
Radiol Med. 2011 Oct;116(7):1050-8. English, Italian. doi:
Zoller P, Inguscio M, Dalmonte M, Fallani L. Observation of chiral edge states
with neutral fermions in synthetic Hall ribbons. Science. 2015 Sep
25;349(6255):1510-3. doi: 10.1126/science.aaa8736. PMID: 26404829.
Velikova G, Spry N; EORTC Quality of Life Group. EORTC radiation proctitis-
specific quality of life module - pretesting in four European countries.
Radiother Oncol. 2010 Nov;97(2):294-300. doi: 10.1016/j.radonc.2010.04.001. Epub
2010 May 4. PMID: 20447707.
Airoldi M, Moretti G, Ficorella C, Gianni L, Michelotti A, Zambelli A, Febbraro
A, Generali D, Pistelli M, Garrone O, Musolino A, Vici P, Maur M, Mentuccia L,
La Verde N, Bianchi GV, Artale S, Blasi L, De Laurentiis M, Atzori F, Turletti
A, Porpiglia M, Santini D, Fabi A, Gebbia V, Schirone A, Palumbo R, Ferzi A,
Frassoldati A, Scavelli C, Clivio L, Giordano M, Donadio M, Biganzoli L, Del
Mastro L, Bisagni G, Livi L, Natoli C, Montemurro F, Riccardi F, Romagnoli E,
Marchetti P, Torri V, Pronzato P, Mustacchi G. Is There Still a Role for
Endocrine Therapy Alone in HR+/HER2- Advanced Breast Cancer Patients? Results
from the Analysis of Two Data Sets of Patients Treated with High-Dose
Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13
AMBRA Studies. Breast Care (Basel). 2020 Feb;15(1):30-37. doi:
Bertini N, Mattioli C, Simontacchi G, Francolini G, Greto D, Loi M, Di Cataldo
V, Livi L, Bonomo P. Stereotactic body radiotherapy for lung-only
oligometastatic head and neck squamous cell carcinoma: Long-term clinical
outcome and favorable predictive factors. Eur J Cancer. 2025 Mar 11;218:115260.
doi: 10.1016/j.ejca.2025.115260. Epub 2025 Jan 27. PMID: 39908655.
Fondelli S, Santini R, Valeriani M, Rago L, Bruni A, Augurio A, Trippa F, Russo
D, Tamburo M, Parisi S, Borghesi S, Gomellini S, Scoccianti S, Musio D,
Stefanacci M, Facondo G, Statuto T, Miranda G, Santo B, Di Marzo A, Bellavita R,
Vinciguerra A, Livi L, Aristei C, Detti B. Hypofractionated radiotherapy in
elderly patients (≥75 years) affected by localized prostate cancer: a
multicenter retrospective analysis from the IPOPROMISE study. Prostate Cancer
Prostatic Dis. 2025 Mar 17. doi: 10.1038/s41391-025-00962-z. Epub ahead of
Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group. Safety and
tolerability of subcutaneous trastuzumab for the adjuvant treatment of human
epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase
III study's primary analysis of 2573 patients. Eur J Cancer. 2017
Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16. PMID:
Livi L, Winter J, Tsitsekidis S, Dohm O, Thorwarth D, Zips D, De-Colle C.
Partial breast irradiation with the 1.5 T MR-Linac: First patient treatment and
analysis of electron return and stream effects. Radiother Oncol. 2020
Apr;145:30-35. doi: 10.1016/j.radonc.2019.11.025. Epub 2019 Dec 23. PMID:
Marrazzo L, Di Cataldo V, Bianchi S, Cataliotti L, Biti G. The impact of young
age on breast cancer outcome. Eur J Surg Oncol. 2010 Jul;36(7):639-45. PMID:
307: Marrazzo L, Chilà D, Vanore I, Pellegrini R, Voet P, Di Cataldo V, Meattini
I, Zani M, Arilli C, Calusi S, Casati M, Compagnucci A, Talamonti C, Livi L,
Pallotta S. Planning Automation for Treatment Techniques Comparison and
Robustness Analysis: Tangential Intensity Modulated Radiation Therapy and
Volumetric Modulated Arc Therapy for Whole Breast Irradiation. Adv Radiat Oncol.
2025 Jan 15;10(3):101719. doi: 10.1016/j.adro.2025.101719. PMID: 40092157;
PMCID: PMC11910076.
Sangalli C, Allajbej A, Di Cristina L, Mazzola R, Pontoriero A, Montesi G,
Navarria P, Baldaccini D, Clerici E, Lo Faro L, Franzese C, Di Biase S,
Pergolizzi S, Alongi F, Bignardi M, Fazio I, Mascarin M, Jereczek-Fossa BA, Livi
L, Scorsetti M. Oligometastatic sarcoma treated with Curative intent Ablative
Radiotherapy (OSCAR): A multicenter study on behalf of AIRO (Italian association
of Radiotherapy and clinical Oncology). Radiother Oncol. 2024 Feb;191:110078.
doi: 10.1016/j.radonc.2023.110078. Epub 2023 Dec 30. PMID: 38163485.
Livi L, Mangoni M, Di Cataldo V, Marrazzo L, Rampini A, Cipressi S, Bruni A,
Santini P, Biti G. Post-operative radiotherapy in N2 non-small cell lung cancer:
a retrospective analysis of 175 patients. Radiother Oncol. 2010 Jul;96(1):84-8.
doi: 10.1016/j.radonc.2010.05.010. Epub 2010 Jun 11. PMID: 20541823.
Sanguineti G, Marchetti P, Botticelli A, Marinelli D, Gamucci T, Natoli C,
Grassadonia A, Tinari N, Tomao S, Tonini G, Santini D, Michelotti A, Mentuccia
L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano
A, Cazzaniga M, Moscetti L, Fabbri A, Scinto AF, Corsi D, Carbognin L, Bria E,
La Verde N, Garufi C, Di Stefano P, Mirabelli R, Veltri E, Paris I, Giotta F,
Lorusso V, Landucci E, Ficorella C, Roselli M, Adamo V, Ricciardi G, Russo A,
Valerio MR, Berardi R, Pistelli M, Cannita K, Zamagni C, Garrone O, Baldini E,
Livi L, Meattini I, Del Medico P, Generali D, De Maria R, Risi E, Ciliberto G,
Villa A, Sperduti I, Mazzotta M, Barba M, Giordano A, Vici P. Impact of BMI on
HER2+ metastatic breast cancer patients treated with pertuzumab and/or
trastuzumab emtansine. Real-world evidence. J Cell Physiol. 2020
Nov;235(11):7900-7910. doi: 10.1002/jcp.29445. Epub 2020 Jan 15. PMID: 31943171.
Teriaca MA, Caramia G, Lo Russo M, Olmetto E, Delli Paoli C, Grassi R, Carfora
V, Saieva C, Bonomo P, Detti B, Mangoni M, Desideri I, Francolini G, Di Cataldo
V, Marrazzo L, Pallotta S, Livi L. Dosimetric Predictors of Acute and Chronic
Alopecia in Primary Brain Cancer Patients Treated With Volumetric Modulated Arc
32322558; PMCID: PMC7156544.
J, Jung W, Olmetto E, Mariotti M, Desideri I, Fourquet A, Livi L, Kim K.
Hypofractionated whole breast irradiation after conservative surgery for
patients aged less than 60 years: a multi-centre comparative study. Acta Oncol.
2020 Feb;59(2):188-195. doi: 10.1080/0284186X.2019.1695061. Epub 2019 Nov 25.
PMID: 31760849.
Muntoni C, Becherini C, Topulli J, Campanacci D, Beltrami G, Scoccianti G,
Muratori F, Bonomo P, Desideri I, Francolini G, Livi L. Influence of age and
subtype in outcome of operable liposarcoma. Radiol Med. 2019 Apr;124(4):290-300.
doi: 10.1007/s11547-018-0958-4. Epub 2018 Nov 12. PMID: 30421387.
Fiore MS, Gerardi MA, Pepa M, Gugliandolo SG, Livi L, Orecchia R, Jereczek-Fossa
BA, Dicuonzo S. The emerging role of radiation therapists in the contouring of
organs at risk in radiotherapy: analysis of inter-observer variability with
radiation oncologists for the chest and upper abdomen. Ecancermedicalscience.
2020 Jan 6;14:996. doi: 10.3332/ecancer.2020.996. PMID: 32153651; PMCID:
Talamonti C, Scoccianti S, Greto D, Bordi L, Livi L, Pallotta S. γTools: A
modular multifunction phantom for quality assurance in GammaKnife treatments.
Phys Med. 2017 Nov;43:34-42. doi: 10.1016/j.ejmp.2017.10.010. Epub 2017 Oct 21.
PMID: 29195560.
Livi L, Simontacchi G, Desideri I, Lisci R. ADAM phantom to test 4D medical
imaging and dose delivery devices. Phys Med Biol. 2019 May 8;64(10):105002. doi:
Desideri I, Francolini G, Bonomo P, Greto D, Loi M, Mangoni M, Bruni A, Nori J,
Vezzosi V, Bianchi S, Livi L. Triple Negative Apocrine Carcinomas as a Distinct
Subtype of Triple Negative Breast Cancer: A Case-control Study. Clin Breast
Gelibter A, Cappuzzo F, Turci D, Gamucci T, Antonelli P, Marchetti P, Santoro A,
Giusti S, Di Costanzo F, Giustini L, Del Conte A, Livi L, Giannarelli D, de
Marinis F. Use of nivolumab in elderly patients with advanced squamous non-
small-cell lung cancer: results from the Italian cohort of an expanded access
Epub 2018 Jul 13. PMID: 30014881.
Triggiani L, Greto D, Rubino L, Livi L, Bertoni F, Magrini SM. Reirradiation in
head and neck recurrent or second primary tumor: efficacy, safety, and
prognostic factors. Tumori. 2015 Sep-Oct;101(5):585-92. doi: 10.5301/tj.5000368.
Epub 2015 Jun 15. PMID: 26108237.
Bonomo P, Nori J, Casella D, Simoncini R, Orzalesi L, Bianchi S, Livi L.
Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast
radiotherapy: a single institution series. Med Oncol. 2014 Apr;31(4):891. doi:
Gabbrielli S, Giannotti E, Lucci F, Vezzosi V, De Benedetto D, Bicchierai G,
Bianchi S, Sanchez L, Orzalesi L, Carmelo G, Miele V, Livi L, Casella D. The
Evolving Role of Ultrasound Guided Percutaneous Laser Ablation in Elderly
Unresectable Breast Cancer Patients: A Feasibility Pilot Study. Biomed Res Int.
2018 Jun 11;2018:9141746. doi: 10.1155/2018/9141746. PMID: 29992167; PMCID:
I, Livi L, Deganello A. Biomarkers in wound drainage fluids of head and neck
squamous cell carcinoma patients receiving neck dissection: A pilot study. Clin
Transl Radiat Oncol. 2020 Apr 23;23:60-64. doi: 10.1016/j.ctro.2020.04.008.
PMID: 32435703; PMCID: PMC7231969.
D'Onofrio A, Rubino L, Frassinelli L, Salvestrini V, Mariotti M, Alongi F,
Gonfiotti A, Livi L, Scotti V. The role of postoperative radiotherapy for
thymomas: a multicentric retrospective evaluation from three Italian centers and
review of the literature. J Thorac Dis. 2020 Dec;12(12):7518-7530. doi:
V, Casella D, Simoncini R, Orzalesi L, Nori J, Paglierani M, Livi L. Multiple
cutaneous angiosarcomas after breast conserving surgery and bilateral adjuvant
radiotherapy: an unusual case and review of the literature. Case Rep Oncol Med.
2014;2014:413030. doi: 10.1155/2014/413030. Epub 2014 Mar 5. PMID: 24744928;
PMCID: PMC3972881.
C, Cai T, Pertici M, Giacomelli I, Livi L, Ceroti M, Nicita G, Carini M, Biti G.
Adjuvant and salvage radiotherapy after prostatectomy: outcome analysis of 307
patients with prostate cancer. J Cancer Res Clin Oncol. 2013 Jan;139(1):147-57.
doi: 10.1007/s00432-012-1309-9. Epub 2012 Sep 18. PMID: 22986810.
A, Scoccianti S, Piperno G, Biti G. Treatment of uterine sarcoma at the
University of Florence from 1980-2001. Tumori. 2005 Mar-Apr;91(2):139-43. doi:
Learning in Graph Neural Networks With Node Decimation Pooling. IEEE Trans
Neural Netw Learn Syst. 2022 May;33(5):2195-2207. doi:
Bucciolini M, Livi L. Four-dimensional computed tomography in accelerated
partial breast irradiation planning: single series from a phase III trial.
Radiol Med. 2015 Nov;120(11):1078-82. doi: 10.1007/s11547-015-0541-1. Epub 2015
Apr 24. PMID: 25907992.
Jereczek-Fossa BA, Livi L, Pergolizzi S, Scorsetti M, Corvò R, Magrini SM. In
reply to Fiorino et al.: The central role of the radiation oncologist in the
multidisciplinary & multiprofessional model of modern radiation therapy.
Radiother Oncol. 2021 Feb;155:e20-e21. doi: 10.1016/j.radonc.2020.11.034. Epub
2020 Dec 30. PMID: 33387582.
Angelino F, Chiesa F, Saieva C, Vanzi E, Boeri C, Bianchi S, Sanchez L, Orzalesi
L, Casella D, Susini T, Livi L. Role of preoperative breast MRI in ductal
carcinoma in situ for prediction of the presence and assessment of the extent of
occult invasive component. Breast J. 2014 May-Jun;20(3):243-8. doi:
Bicchierai G, Di Naro F, Gill MK, Orzalesi L, Sanchez L, Susini T, Bianchi S,
Livi L, Miele V. Corrigendum to "Role of Magnetic Resonance Imaging in the
Preoperative Staging and Work-Up of Patients Affected by Invasive Lobular
Carcinoma or Invasive Ductolobular Carcinoma". Biomed Res Int. 2018 Sep
6;2018:9056239. doi: 10.1155/2018/9056239. Erratum for: Biomed Res Int. 2018 Jun
Barba M, Maugeri-Saccà M, Gamucci T, Berardi R, Livi L, Ficorella C, Natoli C,
Cortesi E, Generali D, La Verde N, Cassano A, Bria E, Moscetti L, Michelotti A,
Adamo V, Zamagni C, Tonini G, Barchiesi G, Mazzotta M, Marinelli D, Tomao S,
Marchetti P, Valerio MR, Mirabelli R, Russo A, Fabbri MA, D'Ostilio N, Veltri E,
Corsi D, Garrone O, Paris I, Sarobba G, Giotta F, Garufi C, Cazzaniga M, Del
Medico P, Roselli M, Sanguineti G, Sperduti I, Sapino A, De Maria R, Leonetti C,
Di Leo A, Ciliberto G, Falcioni R, Vici P. Loss of HER2 and decreased T-DM1
efficacy in HER2 positive advanced breast cancer treated with dual HER2
blockade: the SePHER Study. J Exp Clin Cancer Res. 2020 Dec 10;39(1):279. doi:
L, Sanchez LJ, Bernini M, Casella D, Nesi S, Nori J, Bianchi S, Pallotta S,
Marrazzo L. External accelerated partial breast irradiation for ductal carcinoma
in situ: long-term follow-up from a phase 3 randomized trial. Tumori. 2019
Jun;105(3):205-209. doi: 10.1177/0300891618811278. Epub 2018 Nov 26. PMID:
Lenir C, Lesur A, Kerbrat P, Provencio M, Gonzague-Casabianca L, Mege A,
Lemanski C, Delva C, Lancrenon S, Velten M. Breast cancer occurred after
Hodgkin's disease: clinico-pathological features, treatments and outcome:
analysis of 214 cases. Crit Rev Oncol Hematol. 2012 Jan;81(1):29-37. doi:
Blind and Sighted Scuba Divers: Comparative study. Sultan Qaboos Univ Med J.
2017 May;17(2):e168-e173. doi: 10.18295/squmj.2016.17.02.006. Epub 2017 Jun 20.
PMID: 28690888; PMCID: PMC5488817.
Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C,
Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone
A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A,
Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L,
Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La
Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM,
D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M,
Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M,
Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C,
Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del
Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I,
Villa A, Barba M, Di Leo A, Vici P. Distinct HR expression patterns
significantly affect the clinical behavior of metastatic HER2+ breast cancer and
degree of benefit from novel anti-HER2 agents in the real world setting. Int J
PMID: 31330065; PMCID: PMC7027476.
Calvani N, Facchini G, De Placido S, Airoldi M, Sbrana A, Gasparro D, Ludovico
GM, Guglielmini P, Naglieri E, Fagnani D, Aglietta M, Schips L, Beccaglia P,
Sciarra A, Livi L, Santini D. Effectiveness of abiraterone acetate plus
prednisone in chemotherapy-naïve patients with metastatic castration-resistant
prostate cancer in a large prospective real-world cohort: the ABItude study.
Ther Adv Med Oncol. 2020 Oct 29;12:1758835920968725. doi:
A, Belgioia L, Franzese C, Lopci E, Casolo A, D'Angelo E, Alterio D, Travaini L,
Berretta L, Pirro V, Ursino S, Volterrani D, Roncali M, Vigo F, Cicchetti S,
Scalone F, Belli G, Cauda S, Desideri I, Russi E, Livi L, Bianchi A. Does a
6-point scale approach to post-treatment 18F-FDG PET-CT allow to improve
response assessment in head and neck squamous cell carcinoma? A multicenter
Detti B, Scoccianti S, Biti G. Breast cancer following Hodgkin's Disease: the
experience of the University of Florence. Breast J. 2010 May-Jun;16(3):290-6.
doi: 10.1111/j.1524-4741.2010.00904.x. Epub 2010 Feb 23. PMID: 20210800.
V, Scoccianti S, Paiar F, Bordi L, Nori J, Sanchez L, Orzalesi L, Bianchi S,
Biti G. Prognostic factors and clinical features in patients with leptominengeal
metastases from breast cancer: a single center experience. J Chemother. 2012
Oct;24(5):279-84. doi: 10.1179/1973947812Y.0000000034. PMID: 23182047.
Scartoni D, Cecchini S, Sanchez LJ, Orzalesi L, Casella D, Bianchi S, Livi L,
Nori J. The impact of method of biopsy on the incidence of breast cancer
sentinel lymph node metastases. Eur J Surg Oncol. 2014 Mar;40(3):277-81. doi:
Regard to Boero et al. Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):855-6.
doi: 10.1016/j.ijrobp.2016.01.024. PMID: 27131087.
Paiar F, Simontacchi G, Meattini I, Greto D, Agresti B, Livi L, Biti G. Salvage
stereotactic re-irradiation with CyberKnife for locally recurrent head and neck
cancer: a single center experience. Tumori. 2014 May-Jun;100(3):278-83. doi:
L, Muntoni C, Olmetto E, Francolini G, Turkaj A, Topulli J, Ciabatti C, Carta G,
Poggesi L, Delli Paoli C, Terziani F, Grassi R, Livi L. High-dose intensity-
modulated radiation therapy as primary treatment of prostate cancer:
genitourinary/gastrointestinal toxicity and outcomes, a single-institution
Epub 2019 Jan 3. PMID: 30607866.
P, Scoccianti G, Beltrami G, Greto D, Livi L, Baldi G, Roselli G, Capanna R,
Campanacci DA. Liposarcoma: Clinico-pathological analysis, prognostic factors
and survival in a series of 307 patients treated at a single institution. J
Orthop Sci. 2018 Nov;23(6):1038-1044. doi: 10.1016/j.jos.2018.06.008. Epub 2018
Jul 11. PMID: 30007495.
Tomatis S, Becherini C, Livi L, Scorsetti M. The Potential Role of Intensity-
modulated Proton Therapy in the Regional Nodal Irradiation of Breast Cancer: A
Treatment Planning Study. Clin Oncol (R Coll Radiol). 2020 Jan;32(1):26-34. doi:
the dosimetric accuracy of volumetric modulated arc therapy. Med Phys. 2013
Jul;40(7):071718. doi: 10.1118/1.4810969. PMID: 23822422.
Lancellotta V, Rossi F, Saieva C, Desideri I, Delli Paoli C, D'Angelo E,
Triggiani L, Bastiani P, Alongi F, Lozza L, Aristei C, Ricardi U, Scorsetti M,
Livi L; Clinical Oncology Breast Cancer Group (COBCG) Investigators. A national
multicenter study on 1072 DCIS patients treated with breast-conserving surgery
and whole breast radiotherapy (COBCG-01 study). Radiother Oncol. 2019
Feb;131:208-214. doi: 10.1016/j.radonc.2018.07.015. Epub 2018 Jul 31. PMID:
Bonomo P, Loi M, Greto D, Visani L, Lo Russo M, Grassi R, Teriaca MA, Garlatti
P, Nardi C, Livi L. Efficacy and Tolerability of CyberKnife Stereotactic Robotic
Radiotherapy for Primary or Secondary Orbital Lesions: A Single-Center
Retrospective Experience. Technol Cancer Res Treat. 2019 Jan
1;18:1533033818818561. doi: 10.1177/1533033818818561. PMID: 30803353; PMCID:
Mondaini N, Nelli F, Bastiani P, Pertici M, Mungai R, Ponticelli P, Biti G.
Localized prostate cancer treated with intensity-modulated radiotherapy. Tumori.
2006 May-Jun;92(3):197-201. doi: 10.1177/030089160609200302. PMID: 16869235.
Bruni A, Paiar F, Mangoni M, Marrazzo L, Agresti B, Cataliotti L, Bianchi S,
Biti G. Radiotherapy timing in 4,820 patients with breast cancer: university of
florence experience. Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):365-9. doi:
F, Voltolini L. Afatinib with subsequent surgery in stage III NSCLC with EGFR
mutation: Lessons learned from two clinical experiences. Tumori. 2018
Dec;104(6):NP5-NP9. doi: 10.1177/0300891618775204. Epub 2018 Jun 13. PMID:
C, Perna M, Campanacci D, Terziani F, Beltrami G, Scoccianti G, Bonomo P,
Meattini I, Desideri I, Simontacchi G, Mangoni M, Livi L. Safety of concurrent
adjuvant radiotherapy and chemotherapy for locally advanced soft tissue sarcoma.
Costantini AS, Gorini G. Association between genetic polymorphisms in the XRCC1,
XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT genes and radiosensitivity
in breast cancer patients. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):52-8.
doi: 10.1016/j.ijrobp.2010.04.023. Epub 2010 Aug 12. PMID: 20708344.
Marrazzo L, Pallotta S, Meacci F, Muntoni C, Bendinelli B, Sanchez LJ, Bernini
M, Orzalesi L, Nori J, Bianchi S, Livi L. Accelerated partial breast irradiation
using intensity modulated radiotherapy versus whole breast irradiation: Health-
related quality of life final analysis from the Florence phase 3 trial. Eur J
PMID: 28262584.
Calonico D, Catani J, Inguscio M, Fallani L. Synthetic Dimensions and Spin-Orbit
Coupling with an Optical Clock Transition. Phys Rev Lett. 2016 Nov
25;117(22):220401. doi: 10.1103/PhysRevLett.117.220401. Epub 2016 Nov 23. PMID:
Delli Paoli C, Pezzulla D, Loi M, Bonomo P, Greto D, Calusi S, Casati M,
Pallotta S, Livi L. Assessment of a guideline-based heart substructures
delineation in left-sided breast cancer patients undergoing adjuvant
radiotherapy : Quality assessment within a randomized phase III trial testing a
cardioprotective treatment strategy (SAFE-2014). Strahlenther Onkol. 2019
Jan;195(1):43-51. English. doi: 10.1007/s00066-018-1388-x. Epub 2018 Nov 7.
PMID: 30406290.
Finazzi Agro E, Li Marzi V, Minervini A, Carini M, Oelke M, Gravas S, Serni S.
Bladder Instillation Therapy With Hyaluronic Acid and Chondroitin Sulfate
Improves Symptoms of Postradiation Cystitis: Prospective Pilot Study. Clin
Genitourin Cancer. 2016 Oct;14(5):444-449. doi: 10.1016/j.clgc.2016.01.016. Epub
2016 Feb 8. PMID: 26953222.
Capanna R, Baldi G, Campanacci DA. Leiomyosarcoma: Clinicopathological study and
retrospective analysis of prognostic factors in a series of 100 patients. J
30976144; PMCID: PMC6441716.
E, Loi M, Perna M, Meattini I, Scotti V, Greto D, Bonomo P, Sulprizio S, Livi L.
Use of an alpha lipoic, methylsulfonylmethane and bromelain dietary supplement
(Opera<sup>®</sup>) for chemotherapy-induced peripheral neuropathy management, a
prospective study. Med Oncol. 2017 Mar;34(3):46. doi: 10.1007/s12032-017-0907-4.
Epub 2017 Feb 15. PMID: 28205185.
Delli Paoli C, Olmetto E, Visani L, Meattini I, Greto D, Bonomo P, Loi M, Detti
B, Livi L. Benefit of ablative versus palliative-only radiotherapy in
combination with nivolumab in patients affected by metastatic kidney and lung
S, Bianchi S, Cardona G, Biti GP. Tubular carcinoma of the breast: outcome and
loco-regional recurrence in 307 patients. Eur J Surg Oncol. 2005 Feb;31(1):9-12.
doi: 10.1016/j.ejso.2004.09.002. PMID: 15642419.
S, Greto D, Scoccianti S, Livi L. Oral Lapacho-Based Medication: An Easy, Safe,
and Feasible Support to Prevent and/or Reduce Oral Mucositis During Radiotherapy
for Head and Neck Cancer. Nutr Cancer. 2015;67(8):1247-53. doi:
Saec O, Coscarelli S, Mannelli G. Analysis of dysphagia in advanced-stage head-
and-neck cancer patients: impact on quality of life and development of a
preventive swallowing treatment. Eur Arch Otorhinolaryngol. 2018
Aug;275(8):2159-2167. doi: 10.1007/s00405-018-5054-9. Epub 2018 Jul 5. PMID:
Francolini G, Bonomo P, Livi L. CyberKnife MLC-based treatment planning for
abdominal and pelvic SBRT: Analysis of multiple dosimetric parameters, overall
scoring index and clinical scoring. Phys Med. 2018 Dec;56:25-33. doi:
De Biase P, Detti B, Fondelli S, Meldolesi E, Pertici M, Polli C, Simontacchi G,
Biti G. Late treatment-related complications in 214 patients with extremity
soft-tissue sarcoma treated by surgery and postoperative radiation therapy. Am J
G, Viggiano D, Lanfranchi B, Gonfiotti A, Topulli J, Olmetto E, Maragna V,
Ferrari K, Bonti V, Comin C, Balduzzi S, D'Amico R, Lohr F, Voltolini L, Livi L.
Stereotactic Ablative Radiotherapy as an Alternative to Lobectomy in Patients
With Medically Operable Stage I NSCLC: A Retrospective, Multicenter Analysis.
Clin Lung Cancer. 2019 Jan;20(1):e53-e61. doi: 10.1016/j.cllc.2018.09.003. Epub
2018 Sep 8. PMID: 30348595.
Galaverni M, Amelio D, Scartoni D, Scoccianti S, Krengli M, Masini L, Draghini
L, Maranzano E, Borzillo V, Muto P, Ferrarese F, Fariselli L, Livi L,
Pasqualetti F, Fiorentino A, Alongi F, di Monale MB, Magrini S, Scorsetti M. Re-
irradiation for recurrent glioma: outcome evaluation, toxicity and prognostic
factors assessment. A multicenter study of the Radiation Oncology Italian
Association (AIRO). J Neurooncol. 2019 Mar;142(1):59-67. doi:
Ravaioli A, Rossi AP, Gambi A, Luzi Fedeli S, Perroni D, Scarpi E, Becciolini A,
Silvestrini R. Phase III randomized multicenter study on the effects of adjuvant
CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-
year results and retrospective subgroup analysis. Breast Cancer Res Treat. 2008
Mar;108(2):259-64. doi: 10.1007/s10549-007-9593-9. Epub 2007 May 26. PMID:
Miracco C, Meliani E, Carini M, Livi L, Zanna I, Trovarelli S, Marino V,
Vignolini G, Pomara G, Orlando V, Giubilei G, Selli C, Rizzo M. Clinical
characteristics and overall survival in genitourinary sarcomas treated with
curative intent: a multicenter study. Eur Urol. 2005 Apr;47(4):468-73. doi:
Livi L, Miele V. Role of Magnetic Resonance Imaging in the Preoperative Staging
and Work-Up of Patients Affected by Invasive Lobular Carcinoma or Invasive
Ductolobular Carcinoma. Biomed Res Int. 2018 Jun 26;2018:1569060. doi:
30046588; PMCID: PMC6038675.
Defferrari C, Spada M, Masini C, Santini D, Ciuffreda L, Ruggeri EM, Bengala C,
Livi L, Fagnani D, Bonetti A, Giustini L, Hamzaj A, Procopio G, Caserta C,
Sabbatini R. Efficacy and safety data in elderly patients with metastatic renal
cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy.
PLoS One. 2018 Jul 6;13(7):e0199642. doi: 10.1371/journal.pone.0199642. PMID:
29979712; PMCID: PMC6034807.
G, Delli Paoli C, Grassi R, Pezzulla D, Greto D, Meattini I, Livi L. Elderly
patients affected by head and neck squamous cell carcinoma unfit for standard
curative treatment: Is de-intensified, hypofractionated radiotherapy a feasible
strategy? Oral Oncol. 2017 Nov;74:142-147. doi:
L, Doino D, Fiorentino A, Masini L, Greto D, Buglione M, Rubino G, Lonardi F,
Migliaccio F, Marzano S, Santoni R, Ricardi U, Livi L. Hypofractionated
radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good
prognosis patients with glioblastoma: a multicenter phase II study by the Brain
Study Group of the Italian Association of Radiation Oncology (AIRO). Radiol Med.
2018 Jan;123(1):48-62. doi: 10.1007/s11547-017-0806-y. Epub 2017 Sep 6. PMID:
Paoletti L, Doria M, Desideri I, Terziani F, De Luca Cardillo C, Bendinelli B,
Ciabatti C, Muntoni C, Tinacci G, Nori J, Smith H, Brancato B, Galli L, Sanchez
LJ, Casella D, Bernini M, Orzalesi L, Carta GA, Bianchi S, Rossi F, Livi L.
Impact of hormonal status on outcome of ductal carcinoma in situ treated with
breast-conserving surgery plus radiotherapy: Long-term experience from two
large-institutional series. Breast. 2017 Jun;33:139-144. doi:
R, Rinaldi S, Regolo L, Amanti C, Roncella M, Serra M, Meneghini G, Bortolini M,
Altomare V, Cabula C, Catalano F, Cirilli A, Caruso F, Lazzaretti MG, Meattini
I, Livi L, Cataliotti L, Bernini M. Current trends and outcomes of breast
reconstruction following nipple-sparing mastectomy: results from a national
multicentric registry with 1006 cases over a 6-year period. Breast Cancer. 2017
May;24(3):451-457. doi: 10.1007/s12282-016-0726-z. Epub 2016 Sep 6. PMID:
Arcangeli S, Lund JA, Kristensen A, McFadden N, Grun A, Bydder S, Sackerer I,
Greimel E, Spry N; EORTC Quality of Life Group. International validation of the
EORTC QLQ-PRT20 module for assessment of quality of life symptoms relating to
radiation proctitis: a phase IV study. Radiat Oncol. 2018 Aug 29;13(1):162. doi:
Greto D, Pallotta S, Livi L. Anti PD-L1 DUrvalumab combined with Cetuximab and
RadiOtherapy in locally advanced squamous cell carcinoma of the head and neck: A
phase I/II study (DUCRO). Clin Transl Radiat Oncol. 2018 Feb 7;9:42-47. doi:
29;27:96-97. doi: 10.1016/j.ctro.2020.11.008. PMID: 29594250; PMCID: PMC5862684.
Camporeale J, Muss H, Marks LB, Livi L, Mayer DK, Zagar TM. The use of
psychological supportive care services and psychotropic drugs in patients with
early-stage breast cancer: a comparison between two institutions on two
2017 Jul 19. PMID: 28726045.
Gravas S, Carini M, Serni S. Corrigendum to "Quality of Life and Sexual Health
in the Aging of PCa Survivors". Int J Endocrinol. 2015;2015:675101. doi:
2014;2014:470592. doi: 10.1155/2014/470592. PMID: 25763069; PMCID: PMC4339704.
F, Furfaro IF, Muntoni C, Scoccianti S, Detti B, Mangoni M, Nori J, Orzalesi L,
Fambrini M, Bianchi S, Livi L. Aprepitant as prophylaxis of chemotherapy-induced
nausea and vomiting in anthracyclines and cyclophosphamide-based regimen for
adjuvant breast cancer. Med Oncol. 2015 Mar;32(3):80. doi:
NA, Becherini C, Visani L, Salvestrini V, Mariotti M, Livi L. Clinical outcome
of stereotactic body radiotherapy for lung-only oligometastatic head and neck
squamous cell carcinoma: Is the deferral of systemic therapy a potential goal?
Oral Oncol. 2019 Jun;93:1-7. doi: 10.1016/j.oraloncology.2019.04.006. Epub 2019
Apr 8. PMID: 31109688.
C, Delli Paoli C, Visani L, Salvestrini V, De Feo ML, Nori J, Bernini M, Sanchez
L, Orzalesi L, Bianchi S, Meattini I. Phase 2 placebo-controlled, single-blind
trial to evaluate the impact of oral ibandronate on bone mineral density in
osteopenic breast cancer patients receiving adjuvant aromatase inhibitors:
5-year results of the single-centre BONADIUV trial. Eur J Cancer. 2019
Feb;108:100-110. doi: 10.1016/j.ejca.2018.12.005. Epub 2019 Jan 14. PMID:
Simontacchi G, Pimpinelli N, Livi L. Management of severe bio-radiation
dermatitis induced by radiotherapy and cetuximab in patients with head and neck
cancer: emphasizing the role of calcium alginate dressings. Support Care Cancer.
2019 Aug;27(8):2957-2967. doi: 10.1007/s00520-018-4606-2. Epub 2018 Dec 19.
PMID: 30569265.
Bucciolini M. Surface imaging, portal imaging, and skin marker set-up vs. CBCT
for radiotherapy of the thorax and pelvis. Strahlenther Onkol. 2015
Sep;191(9):726-33. doi: 10.1007/s00066-015-0861-z. Epub 2015 Jun 19. PMID:
Livi L, Iotti C, Botto B, Vaggelli L, Re A, Merli F, Ricardi U. Interim PET
After Two ABVD Cycles in Early-Stage Hodgkin Lymphoma: Outcomes Following the
Continuation of Chemotherapy Plus Radiotherapy. Int J Radiat Oncol Biol Phys.
2015 Aug 1;92(5):1077-1083. doi: 10.1016/j.ijrobp.2015.04.021. Epub 2015 Apr 17.
PMID: 26031367.
Campanacci DA, Capanna R. Limb salvage surgery in combination with brachytherapy
and external beam radiation for high-grade soft tissue sarcomas. Eur J Surg
PMID: 17981427.
F, Scarselli G. Radiofrequency ablation for minimally invasive treatment of
breast carcinoma. A pilot study in elderly inoperable patients. Gynecol Oncol.
2007 Feb;104(2):304-10. doi: 10.1016/j.ygyno.2006.08.049. Epub 2006 Oct 27.
PMID: 17070572.
Bonomo P, Marrazzo L, Casati M, Livi L, Biti G. Simultaneous integrated boost-
intensity-modulated radiotherapy in head and neck cancer. Laryngoscope. 2013
Dec;123(12):E97-103. doi: 10.1002/lary.24257. Epub 2013 Jun 26. PMID: 23775348.
E, Desideri I, Scotti V, Nori J, Sanchez LJ, Orzalesi L, Bonomo P, Greto D,
Bianchi S, Biti G. Radiotherapy boost dose-escalation for invasive breast cancer
after breast-conserving surgery: 2093 patients treated with a prospective
margin-directed policy. Radiother Oncol. 2013 Aug;108(2):273-8. doi:
Late solitary metastasis of cutaneous malignant melanoma presenting as abnormal
uterine bleeding. J Obstet Gynaecol Res. 2008 Aug;34(4 Pt 2):731-4. doi:
J, Cecconi L, Meattini I, Livi L, Bernini M. Microinvasive breast cancer:
pathological parameters, cancer subtypes distribution, and correlation with
axillary lymph nodes invasion. Results of a large single-institution series.
Breast Cancer. 2016 Jul;23(4):640-8. doi: 10.1007/s12282-015-0616-9. Epub 2015
May 17. PMID: 25981971.
Gacci M, Pupi A, Vaggelli L, Saieva C, Pertici M, Livi L, Ceroti M, Nicita G,
Carini M, Biti G. Predictive factors of [18F]-Choline PET/CT in 170 patients
with increasing PSA after primary radical treatment. J Cancer Res Clin Oncol.
2013 Mar;139(3):521-8. doi: 10.1007/s00432-012-1354-4. Epub 2012 Nov 27. PMID:
Livi L. Response to Letter to the Editor Titled "Surgery or Stereotactic Body
Radiotherapy for Early Stage Lung Cancer: What is the Current Evidence?". Clin
Lung Cancer. 2020 Jan;21(1):e35-e36. doi: 10.1016/j.cllc.2019.06.016. Epub 2019
Jun 19. PMID: 31302009.
F, Bendinelli B, Francolini G, Desideri I, De Luca Cardillo C, Scotti V, Furfaro
IF, Rossi F, Greto D, Bonomo P, Casella D, Bernini M, Sanchez L, Orzalesi L,
Simoncini R, Nori J, Bianchi S, Livi L. Accelerated partial breast irradiation
using intensity-modulated radiotherapy technique compared to whole breast
irradiation for patients aged 70 years or older: subgroup analysis from a
randomized phase 3 trial. Breast Cancer Res Treat. 2015 Oct;153(3):539-47. doi:
Livi L, Agresti B, Fambrini M, Marchionni M, Biti G. Postoperative radiotherapy
in stage I/II endometrial cancer: retrospective analysis of 883 patients treated
at the University of Florence. Int J Gynecol Cancer. 2010 Dec;20(9):1540-8.
PMID: 21370597.
CD, Paiar F, Mangoni M, Marrazzo L, Agresti B, Cataliotti L, Bianchi S, Biti G.
Outcome after conservative surgery and breast irradiation in 5,717 patients with
breast cancer: implications for supraclavicular nodal irradiation. Int J Radiat
Oncol Biol Phys. 2010 Mar 15;76(4):978-83. doi: 10.1016/j.ijrobp.2009.03.001.
Epub 2009 Jun 18. PMID: 19540052.
for protein contact networks. J Biomol Struct Dyn. 2016 Jul;34(7):1441-54. doi:
Bastiani P, Cardillo CD, Detti B, Fondelli S, Simontacchi G, Mungai R, Russo S,
Mungai V, Biti G. Accelerated intensity-modulated external radiotherapy as a new
technical approach to treat the index quadrant after conserving surgery in early
breast cancer: a preliminary study. Tumori. 2005 May-Jun;91(3):227-32. doi:
Buglione M, Grisanti S, Almici C, Polli C, Saieva C, Magrini SM, Biti G,
Pazzagli M, Orlando C. Association between single nucleotide polymorphisms in
the XRCC1 and RAD51 genes and clinical radiosensitivity in head and neck cancer.
Radiother Oncol. 2011 Jun;99(3):356-61. doi: 10.1016/j.radonc.2011.05.062. Epub
2011 Jun 23. PMID: 21704413.
Bendinelli B, Scotti V, De Luca Cardillo C, Nori J, Sanchez L, Orzalesi L,
Bonomo P, Greto D, Bucciolini M, Bianchi S, Biti G. Role of radiotherapy boost
in women with ductal carcinoma in situ: a single-center experience in a series
of 389 patients. Eur J Surg Oncol. 2013 Jun;39(6):613-8. doi:
Desideri I, Villari D, Livi L. In reply to Egger et al.: Lack of benefit from
adjuvant postoperative radiotherapy and issues raised about upfront management
of high- and very-high-risk prostate cancer patients. J Med Imaging Radiat
PMID: 32530567.
S, Bertocci S, Franzese C, De Luca Cardillo C, Zei G, Loi M, Greto D, Mangoni M,
Bonomo P, Livi L, Biti GP. Impact of a breathing-control system on target
margins and normal-tissue sparing in the treatment of lung cancer: experience at
the radiotherapy unit of Florence University. Radiol Med. 2014 Jan;119(1):13-9.
doi: 10.1007/s11547-013-0307-6. Epub 2013 Nov 15. PMID: 24234184.
Paiar F, Scoccianti S, Pallotta S, Detti B, Agresti B, Talamonti C, Mangoni M,
Bianchi S, Cataliotti L, Marrazzo L, Bucciolini M, Biti G. Accelerated partial
breast irradiation with IMRT: new technical approach and interim analysis of
acute toxicity in a phase III randomized clinical trial. Int J Radiat Oncol Biol
Bonucci I, Agresti B, Simontacchi G, Doro R. Stereotactic radiotherapy for
adrenal gland metastases: university of Florence experience. Int J Radiat Oncol
Biol Phys. 2012 Feb 1;82(2):919-23. doi: 10.1016/j.ijrobp.2010.11.060. Epub 2011
Feb 6. PMID: 21300473.
I, Scartoni D, Cecchini S, Desideri I, Ferrari K, Bruni A, De Luca Cardillo C,
Bastiani P, Agresti B, Mangoni M, Livi L, Biti G. Radiotherapy timing in the
treatment of limited-stage small cell lung cancer: the impact of thoracic and
brain irradiation on survival. Tumori. 2014 May-Jun;100(3):289-95. doi:
Masoni T, Finazzi Agro E, Li Marzi V, Minervini A, Carini M, Gravas S, Oelke M,
Serni S. Sodium hyaluronate and chondroitin sulfate replenishment therapy can
improve nocturia in men with post-radiation cystitis: results of a prospective
pilot study. BMC Urol. 2015 Jul 7;15:65. doi: 10.1186/s12894-015-0046-1. PMID:
26148853; PMCID: PMC4493946.
IoT network. Rev Sci Instrum. 2021 Sep 1;92(9):094705. doi: 10.1063/5.0060336.
PMID: 34598503.
Simontacchi G, Mangoni M, Paiar F, Ponticelli P, Nori J, Chiavacci A, Biti GP.
Adjuvant hypofractionated radiation therapy for breast cancer after conserving
Biti G. Ischemic stroke during cisplatin-based chemotherapy for testicular germ
cell tumor: case report and review of the literature. J Chemother. 2010
Apr;22(2):134-6. doi: 10.1179/joc.2010.22.2.134. PMID: 20435575.
D, Mangoni M, Meacci F, Loi M, Zei G, Livi L, Biti G. Prognostic factors in
patients with locally advanced head and neck cancer treated with concurrent
Franceschini D, Scotti V, Bonomo P, Nori J, Sanchez L, Vezzosi V, Bianchi S,
Cataliotti L, Biti G. Prognostic value of positive human epidermal growth factor
receptor 2 status and negative hormone status in patients with T1a/T1b, lymph
node-negative breast cancer. Cancer. 2012 Jul 1;118(13):3236-43. doi:
Sanchez L, Nori J, Bertocci S, Cassani S, Bianchi S, Cataliotti L, Biti G. Use
of doxorubicin plus cyclophosphamide followed by docetaxel as adjuvant
chemotherapy for breast cancer. J Chemother. 2011 Feb;23(1):36-9. doi:
Borghesi S, Agresti B, Nosi F, Gavilli S, Biti GP. Alternating intravenous and
oral vinorelbine plus epirubicin with pegfilgrastim as neoadjuvant treatment of
locally advanced breast cancer. Anticancer Drugs. 2006 Oct;17(9):1081-5. doi:
S, Magrini SM. Stage I seminoma of the testis: a bi-institutional retrospective
analysis of patients treated with radiation therapy only. BJU Int. 2003
Jul;92(1):47-52; discussion 52. doi: 10.1046/j.1464-410x.2003.04273.x. PMID:
Meattini I, Pegurri L, Borghetti P, Frata P, Ponticelli P, Buglione M, Biti G. A
benchmark study on 883 nasopharyngeal cancer patients treated in two Italian
centres from 1977 to 2000. Part II: Evolving technical choices and toxicity
Epub 2011 Nov 17. PMID: 22095425.
Mangoni M, Galardi A, Cataliotti L, Paiar F, Bianchi S, Biti G. Adjuvant
trastuzumab in breast cancer: experience from the University of Florence. J
T, Mariani M, Carini M. Quality of life after radical treatment of prostate
cancer: validation of the Italian version of the University of California-Los
Angeles Prostate Cancer Index. Urology. 2005 Aug;66(2):338-43. doi:
Romagnani P, Eisner B, Carini M. Renal cell carcinoma metastatic to the breast
and breast cancer metastatic to the kidney: two rare solitary metastases. Breast
Casati M, Talamonti C, Simontacchi G, Livi L, Pallotta S. Real-time beam
monitoring for error detection in IMRT plans and impact on dose-volume
histograms : A multi-center study. Strahlenther Onkol. 2018 Mar;194(3):243-254.
M, Cancio P, Pizzocaro M, Calonico D, Levi F, Sias C, Catani J, Inguscio M,
Fallani L. Direct observation of coherent interorbital spin-exchange dynamics.
Phys Rev Lett. 2014 Sep 19;113(12):120402. doi: 10.1103/PhysRevLett.113.120402.
Epub 2014 Sep 15. Erratum in: Phys Rev Lett. 2015 Jun 12;114(23):239903. PMID:
L, Fambrini M. A case of metachronous double primary neuroendocrine cancer in
pancreas/ileum and uterine cervix. Ups J Med Sci. 2012 Nov;117(4):453-6. doi:
2003;7(3-4):149-52. doi: 10.1080/13577140310001644760. PMID: 18521379; PMCID:
Vittori G, Giubilei G, Mariani M, Palli D, Carini M. Predictors of quality of
life after radical treatment for prostate cancer. Urol Int. 2008;80(3):231-6.
doi: 10.1159/000127332. Epub 2008 May 14. PMID: 18480622.
two different fiducial gold markers for robotic stereotactic radiosurgery of
liver malignancies: A pilot study. World J Hepatol. 2016 Jun 18;8(17):731-8.
doi: 10.4254/wjh.v8.i17.731. PMID: 27330682; PMCID: PMC4911507.
AM, Iannalfi A, Bruni A, Biti G. Management of Stage II testicular seminoma over
a period of 40 years. Urol Oncol. 2009 Sep-Oct;27(5):534-8. doi:
Villari N, Mascalchi M. Operator-dependent reproducibility of size measurements
of small phantoms and lung nodules examined with low-dose thin-section computed
Greto D, Cataliotti L, Paiar F, Bianchi S, Biti GP. Doxorubicin and
cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil as
adjuvant chemotherapy in breast cancer. J Chemother. 2009 Nov;21(5):558-65. doi:
Pieralli A, Livi L, Scarselli G. Large-muscle endometriosis involving the
adductor tight compartment: case report. J Minim Invasive Gynecol. 2010 Mar-
Apr;17(2):258-61. doi: 10.1016/j.jmig.2009.12.004. PMID: 20226421.
for young members within national radiation oncology societies: the Italian
experience (AIRO Giovani group). Rep Pract Oncol Radiother. 2012 Aug
19;17(5):259-61. doi: 10.1016/j.rpor.2012.07.011. PMID: 24669305; PMCID:
A, Scoccianti S, Paiar F, Cataliotti L, Leonulli BG, Bianchi S, Biti GP.
Concurrent cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy and
radiotherapy for early breast carcinoma. Int J Radiat Oncol Biol Phys. 2008 Jul
1;71(3):705-9. doi: 10.1016/j.ijrobp.2007.10.042. Epub 2008 Jan 11. PMID:
Marrazzo L, Mangoni M, Paiar F, Livi L, Biti G. From a waiting list to a
priority list: a computerized model for an easy-to-manage and automatically
updated priority list in the booking of patients waiting for radiotherapy.
E, Distante V, Simontacchi G, Scoccianti S, Talamonti C, Pallotta S, Biti GP.
The management of elderly patients with T1-T2 breast cancer treated with or
without radiotherapy. Eur J Surg Oncol. 2005 Jun;31(5):473-8. doi:
Treatment of uterine sarcoma at the Royal Marsden Hospital from 1974 to 1998.
Clin Oncol (R Coll Radiol). 2004 Jun;16(4):261-8. doi:
G, Branconi F, Scarselli G. Axillary ultrasound scanning in the follow-up of
breast cancer patients undergoing sentinel node biopsy. Breast. 2007
Apr;16(2):190-6. doi: 10.1016/j.breast.2006.10.004. Epub 2006 Nov 30. PMID:
Criscenti V, Zanna I, Meacci F, Gerlain E, Agresti B, Mangoni M, Paiar F,
Simontacchi G, Greto D, Nori J, Bianchi S, Cataliotti L, Biti G. Treatment of
invasive male breast cancer: a 40-year single-institution experience. Radiol
PMID: 22872459.
Scotti V, Greto D, Bonomo P, Orzalesi L, Bianchi S, Livi L. Predictive factors
for additional non-sentinel lymph node involvement in breast cancer patients
with one positive sentinel node. Tumori. 2015 Jan-Feb;101(1):78-83. doi:
Fossa BA, Filippi AR; AIRO Young and AIRO Prostate cancer Working Group. The
PROCAINA (PROstate CAncer INdication Attitudes) Project (Part I): a survey among
Italian radiation oncologists on postoperative radiotherapy in prostate cancer.
Radiol Med. 2013 Jun;118(4):660-78. doi: 10.1007/s11547-012-0913-8. Epub 2013
Jan 28. PMID: 23358818.
Nosi F, Orzalesi L, Santini R, Barca R, Biti GP. Survival and breast relapse in
3834 patients with T1-T2 breast cancer after conserving surgery and adjuvant
Livi L, Mascalchi M, Scarselli G. Predicting the status of axillary lymph nodes
in breast cancer: a multiparameter approach including axillary ultrasound
2009 Mar 12. PMID: 19285396.
neoadjuvant treatment may have an impact on discordance between preoperative
core needle biopsy and surgical specimen in early breast cancer. Eur J Surg
Mangoni M, Paoletti L, Ponticelli P, Biti GP. Use of tamoxifen in pT1a-pT1b, pN0
breast cancer. Eur J Surg Oncol. 2007 Apr;33(3):271-5. doi:
Paiar F, Barca R, Fondelli S, Polli C, Livi L, Biti G. Radical radiotherapy for
early glottic cancer: Results in a series of 1087 patients from two Italian
radiation oncology centers. II. The case of T2N0 disease. Int J Radiat Oncol
Biol Phys. 2005 Dec 1;63(5):1387-94. doi: 10.1016/j.ijrobp.2005.05.013. Epub
2005 Aug 22. PMID: 16115737.
age on breast cancer outcome. Eur J Surg Oncol. 2010 Jun 5. doi:
Santini R, Scotti V, Bianchi S, Cataliotti L, Mungai V, Biti G. Loco regional
failure pattern after lumpectomy and breast irradiation in 4,185 patients with
T1 and T2 breast cancer. Implications for nodal irradiation. Acta Oncol.
2006;45(5):564-70. doi: 10.1080/02841860600658211. PMID: 16864170.
Echo State Networks Through Fisher Information Maximization. IEEE Trans Neural
Netw Learn Syst. 2018 Mar;29(3):706-717. doi: 10.1109/TNNLS.2016.2644268. Epub
2017 Jan 16. PMID: 28092580.
L; AIRO (Italian Association of Radiation Oncology) and the AIRO Palliative Care
their approach to the treatment of bone metastases. Tumori. 2011 Mar-
Apr;97(2):177-84. doi: 10.1177/030089161109700208. PMID: 21617712.
Olmetto E, Francolini G, Meattini I, Livi L. Prognostic impact of nodal relapse
in definitive prostate-only irradiation. Radiol Med. 2018 Aug;123(8):631-637.
doi: 10.1007/s11547-018-0888-1. Epub 2018 Apr 12. PMID: 29651712.
L, Bonetti B, Vitali E, De Stefani A, Buglione M, Biti G. Radical radiotherapy
for early glottic cancer: Results in a series of 1087 patients from two Italian
radiation oncology centers. I. The case of T1N0 disease. Int J Radiat Oncol Biol
Pagano G, Frittelli M, Mura A, Costanzo GA, Levi F, Calonico D, Fallani L,
Catani J, Inguscio M. Measuring absolute frequencies beyond the GPS limit via
long-haul optical frequency dissemination. Opt Express. 2016 May
30;24(11):11865-75. doi: 10.1364/OE.24.011865. PMID: 27410109.
Franceschini D, Bonomo P, Scotti V, Detti B, Tonelli F, Valeri A, Messerini L,
Biti G. Neoadjuvant oxaliplatin and 5-fluorouracil with concurrent radiotherapy
in patients with locally advanced rectal cancer: a single-institution
Epub 2013 Jan 28. PMID: 23358814.
Parkinsonian Rest Tremors by Analyzing Long-Term Correlations and Multifractal
Fallani L. Strongly Interacting Gas of Two-Electron Fermions at an Orbital
Feshbach Resonance. Phys Rev Lett. 2015 Dec 31;115(26):265301. doi:
Saieva C, Ceroti M, Detti B, Livi L, Pupi A, Carini M. Prostate-specific antigen
kinetics parameters are predictive of positron emission tomography features
worsening in patients with biochemical relapse after prostate cancer treatment
with radical intent: Results from a longitudinal cohort study. Scand J Urol.
2014 Jun;48(3):259-67. doi: 10.3109/21681805.2013.846936. Epub 2013 Nov 21.
PMID: 24255954.
A, Bruni A, Galardi A, Cataliotti L, Biti G. Non-pegylated liposomal doxorubicin
in combination with cyclophosphamide or docetaxel as first-line therapy in
metastatic breast cancer: a retrospective analysis. Tumori. 2009 Jul-
Aug;95(4):422-6. doi: 10.1177/030089160909500402. PMID: 19856650.
Mangoni M, Agresti B, Santomaggio C, Di Cataldo V, Franzese C, Livi L, Magrini
SM, Biti G. Limited-stage small-cell lung cancer treated with early chemo-
radiotherapy: the impact of effective chemotherapy. Tumori. 2012 Jan-
Feb;98(1):53-9. doi: 10.1177/030089161209800107. PMID: 22495702.
Magrini S, Villari D, Carini M, Serio M, Forti G, Pazzagli M, Orlando C. Real-
Time quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for
the measurement of prostate-specific antigen mRNA in the peripheral blood of
patients with prostate carcinoma using the taqman detection system. Clin Chem
Lab Med. 2001 May;39(5):385-91. doi: 10.1515/CCLM.2001.061. PMID: 11434386.
Livi L, Gacci M, Cai T, Greto D, Desideri I, Biti G. Management of stage I
testicular seminoma over a period of 49 years. Onkologie. 2011;34(10):510-4.
doi: 10.1159/000332124. Epub 2011 Sep 19. PMID: 21985849.
Di Brina L, Zei G, Bonomo P, Greto D, Gelain E, Nori J, Sanchez LJ, Orzalesi L,
Bianchi S, Biti G. Prognostic role of human epidermal growth factor receptor 2
status in premenopausal early breast cancer treated with adjuvant tamoxifen.
Clin Breast Cancer. 2013 Aug;13(4):247-53. doi: 10.1016/j.clbc.2013.02.005. Epub
2013 May 15. PMID: 23684167.
Taddei G, Marchionni M. Mini-laparotomy versus vaginal surgery for class II-III
obese patients with early-stage endometrial cancer. Anticancer Res. 2012
Feb;32(2):707-12. PMID: 22287767.
"PROCAINA (PROstate CAncer INdication Attitudes) Project" (Part II)--a survey
among Italian radiation oncologists on radical radiotherapy in prostate cancer.
Radiol Med. 2013 Oct;118(7):1220-39. doi: 10.1007/s11547-013-0925-z. Epub 2013
May 27. PMID: 23716281.
Mangoni M, Fondelli S, Distante V, Bianchi S, Biti G. Breast cancer in the
elderly: treatment of 1500 patients. Breast J. 2006 Jul-Aug;12(4):353-9. doi:
Alongi F, Filippi AR. The STYRO 2011 project: a survey on perceived quality of
training among young Italian radiation oncologists. Med Oncol. 2013
Dec;30(4):729. doi: 10.1007/s12032-013-0729-y. Epub 2013 Sep 27. PMID: 24072510.
M, Pradella R, Spediacci MA, Chiavacci A, Ambrosi E, Livi L, Magli A, Bellavita
R, Bossi A, Biti G. Practice patterns for prostate cancer in nine central and
northern Italy radiation oncology centers: a survey including 1759 patients
treated during two decades (1980-1998). Int J Radiat Oncol Biol Phys. 2002 Apr
1;52(5):1310-9. doi: 10.1016/s0360-3016(01)02783-3. PMID: 11955744.
A, Bruni A, Petrucci A, Biti GP. Loco-regional recurrence in 2064 patients with
breast cancer treated with mastectomy without adjuvant radiotherapy. Eur J Surg
PMID: 17368813.
Sanchez L, Nori J, Mangoni M, Franzese C, Orzalesi L, Bertocci S, Agresti B,
Masoni T, Bianchi S, Cataliotti L, Biti G. Pegylated liposomal doxorubicin
(Caelyx®) and oral vinorelbine in first-line metastatic breast cancer patients
previously treated with anthracyclines. J Chemother. 2011 Jun;23(3):158-62. doi:
Priapism due to sacrococcygeal chordoma metastasis treated with radiation
University of Florence academic teaching courses:
- School of Medicine 2002-2025
- Medical Radiology Techniques for Imaging and Radiotherapy
- Teaching course in nursing
- Postgraduate school in nephrology
- Postgraduate school in Medical Physics
- Postgraduate school in ophthalmology
- Postgraduate schools in medical oncology
- Postgraduate schools in thoracic surgery
- Postgraduate schools in gynecology rehabilitation
- Postgraduate schools in rehabilitation
- Postgraduate schools in anesthesia
- Postgraduate schools in diagnostics imaging
- Postgraduate schools in nuclear medicine
Legenda
